Æâ²Ê³ØÂèÆó¹ÖºÂ

¡Ô¸¦µæ³µÍסÕ

½Û´Ä´ï
¡¡½Û´Ä´ï³Ø¤Ç¤Ï¡¢¿´ÉÔÁ´¤ÎÉÂÂÖ²òÌÀ¤Ë¤Ä¤¤¤Æ¤Î´ðÁø¦µæ¤È¤È¤â¤Ë¡¢µõ·ìÀ­¿´¼À´µ¤äÉÔÀ°Ì®¤Î´µ¼Ôͽ¸å¤ËľÀÜ´Ô¸µ¤Ç¤­¤ëÎ×¾²¸¦µæ¤ò¼çÂΤȤ·¤Æ¤­¤¿¡£

1. ¶É½ê¿´µ¡Ç½¤ÎÄêÎÌŪɾ²ÁË¡¤Ë´Ø¤¹¤ëÎ×¾²Åª¡¢¼Â¸³Åª¸¡Æ¤
¡¡¿´Â¡Ä¶²»ÇÈË¡¤Î¿ÊÊâ¤Ë¤È¤â¤Ê¤¤¡¢È󿯽±Åª¶É½ê¿´µ¡Ç½É¾²Á¤¬²Äǽ¤È¤Ê¤Ã¤Æ¤­¤¿¡£ÆÃ¤Ë¡¢ÁÈ¿¥¥É¥×¥éË¡¤òÍѤ¤¤ì¤ÐÄêÎÌŪ¤Ê¶É½ê¿´µ¡Ç½É¾²Á¤¬²Äǽ¤È¤Ê¤Ã¤Æ¤­¤Æ¤¤¤ë¡£¤½¤³¤Ç¡¢¿´Ë¼ºÙư¤ª¤è¤Óµõ·ìÀ­¿´¼À´µ¤òÂоݤˡ¢ÁÈ¿¥¥É¥×¥éË¡¤Ë¤è¤ë¿´µ¡Ç½É¾²Á¤ÎÍ­ÍÑÀ­¤Ë¤Ä¤¤¤Æ¸¡Æ¤¤·Êó¹ð¤·¤Æ¤­¤¿¡£¤Þ¤¿¡¢Æ°Êª¼Â¸³¤Ë¤ª¤¤¤Æ½¾Íè¤è¤ê»°¼¡¸µ¥¹¥È¥ì¥¤¥ó²òÀϤòÍѤ¤¤¿¶É½ê¿´µ¡Ç½¤Îɾ²Á¤ò¸¡Æ¤¤·¤Æ¤­¤Æ¤¤¤ë¡£¤³¤Î´ðÁÃŪ¸¡Æ¤¤ò¤â¤È¤Ë¡¢ÁÈ¿¥¥É¥×¥éË¡¤òÍѤ¤¤¿¿´µ¡Ç½É¾²Á¤ÎÂÅÅöÀ­¤òưʪ¼Â¸³¤Ë¤ª¤¤¤Æ¤â¸¡Æ¤Ãæ¤Ç¤¢¤ë¡£ÁÈ¿¥¥É¥×¥éË¡¤ò±þÍѤ·¤Æ¡¢¿´Â¡Ä¶²»Çȸ¡ºº¤Ç¤â¥¹¥È¥ì¥¤¥ó²òÀϤ¬Î×¾²Åª¤Ë²Äǽ¤È¤Ê¤Ã¤Æ¤­¤Æ¤ª¤ê¡¢¤³¤ì¤Ë´Ø¤¹¤ëÎ×¾²Åª¡¢¼Â¸³Åª¸¡Æ¤¤ò·Ñ³¤¹¤ëͽÄê¤Ç¤¢¤ë¡£

£². ¿´Â¡¥ê¥Ï¥Ó¥ê¥Æ¡¼¥·¥ç¥ó¡¦±¿Æ°ÎÅË¡¤Ë´Ø¤¹¤ë¸¦µæ
¡¡¿´Â¡¥ê¥Ï¥Ó¥ê¥Æ¡¼¥·¥ç¥ó¤Ï¡¢EBM¤Ë¤â¤È¤Å¤¯¿´¶Ú¹¼ºÉ¸å¤ÎºÆ¹¼ºÉ¡¢¿´ÉÔÁ´¤ÎͽËɰ峨¤È¤·¤Æ³ÎΩ¤µ¤ì¤Æ¤­¤¿¡£º£¸å¡¢±¿Æ°¤Î¤ß¤Ê¤é¤º¡¢±ÉÍÜ¡¢¹Ôư²ðÆþ¤Ê¤É¥«¥¦¥ó¥»¥ê¥ó¥°¤ò´Þ¤à¿Í×ÁÇ¥ê¥Ï¥Ó¥ê¥Æ¡¼¥·¥ç¥ó¤È¤·¤ÆÁí¹çŪ¤Ë»Ü¹Ô¤¹¤ë¤¿¤á¿·¤¿¤Ë·ò¹¯²Ê³Ø¥»¥ó¥¿¡¼¤òÀߤ±Æþ±¡¡¢³°Íè´µ¼Ô¤Ë»Ü¹Ô¤·¤Æ¤¤¤ë¡£Æ±»þ¤ËËýÀ­¿´ÉÔÁ´¤Ë¤ª¤±¤ë¿´µ¡Ç½¤Î²þÁ±¡¢¿´ÉÔÁ´¾õÂ֤ΤΥµ¥¤¥È¥«¥¤¥ó¡¢¼«Î§¿À·Ðµ¡Ç½¤ÎÊѲ½¤Ê¤É¤ò¸¡Æ¤¤·¡¢¤½¤ÎÍ­ÍÑÀ­¤òÊó¹ð¤·¤Æ¤­¤¿¡£¤Þ¤¿¡¢Â¿Í×ÁÇ¥ê¥Ï¤È¤·¤Æ¤Î¹Ôư²ðÆþ¤Ï¡¢¿´¶Ú¹¼ºÉ¤Î¤ß¤Ê¤é¤º¡¢¹â·ì°µ¡¢¹â»é·ì¾É¡¢ÅüǢɤʤÉÀ¸³è½¬´·É¤ËÂФ¹¤ë¼£ÎÅË¡¤È¤·¤ÆÍ­¸ú¤Ç¤¢¤ê¡¢±¿Æ°¸ú²Ì¤ÎºîÍѵ¡½ø¡¢Å¬±þÅù¤òÀ¸ÂÎÆâ¾º°µÊª¼Á¡¢ÈîËþ°äÅÁ»Ò¡¢¥¤¥ó¥¹¥ê¥ó´¶¼õÀ­¡¢»é¼ÁÂå¼Õ¤ÎÌ̤è¤ê¸¦µæ¤·¤Æ¤¤¤ë¡£¤Þ¤¿¡¢·ò¹¯²Ê³Ø¥»¥ó¥¿¡¼¤Ç¤Ï¡¢Î×¾²¥¹¥Ý¡¼¥Ä°å³Ø¤È¤·¤Æ¡¢¥¹¥Ý¡¼¥Ä¿´Â¡¤ÎȯÀ¸µ¡½ø¡¢¸ÆµÛµ¡Ç½¤ÎÁí¹çŪɾ²ÁË¡¤Î³«È¯¤Ê¤É¡¢±¿Æ°À¸Íý³Ø¤ÎÎ×¾²±þÍѤòÌܻؤ·¡¢³Æ¼ï¥¹¥Ý¡¼¥ÄÁª¼ê¤Î±¿Æ°ÂÑÍÆÇ½¡¢¸ÆµÛµ¡Ç½¤òÃæ¿´¤È¤·¤¿Â¬Äê¡¢¥È¥ì¡¼¥Ë¥ó¥°¥á¥Ë¥å¡¼¤Î³«È¯¤ò¹Ô¤Ã¤Æ¤¤¤ë¡£¤³¤ì¤é¤Î¸¦µæ¤Ï¡¢±¿Æ°ÂÑÍÆÇ½Äã²¼¤Ë¤è¤Ã¤Æ°ú¤­µ¯¤³¤µ¤ì¤ë¼À´µ¤ÎÍýÏÀÅªÇØ·Ê¤È¤·¤Æ¤â¸½ºß¸¦µæÃæ¤Ç¤¢¤ë¡£

£³¡¥ËýÀ­¿´ÉÔÁ´Îã¤Ë¤ª¤±¤ë¸ò´¶¿À·Ð³èư¤Ë´Ø¤¹¤ë¸¦µæ
¡¡ËýÀ­¿´ÉÔÁ´¤Ë¤ª¤¤¤Æ¸ò´¶¿À·Ð³èư¤Îж¿Ê¤Ïͽ¸å¤òº¸±¦¤¹¤ë¾å¤Ç½ÅÍפʻØÉ¸¤Ç¤¢¤ë¡£¸ò´¶¿À·Ð³èư¤Î¬Äê¤Ï·ìÃænoradrenaline¡¢¿´ÇïÊÑÆ°¥¹¥Ú¥¯¥È¥é¥à¤Ê¤É¤¬°ìÈÌŪ¤Ç¤¢¤Ã¤¿¤¬¡¢²æ¡¹¤Ï¶Ú¸ò´¶¿À·Ð³èư(MSNA)¤Î¬ÄêÊýË¡¤ò²ñÆÀ¤·¡¢¸ò´¶¿À·Ð³èư¤òľÀÜŪ¤Ë¬Äꤷ¤Æ¤¤¤ë¡£ËýÀ­¿´ÉÔÁ´Îã¤Ë¤ª¤±¤ë¸ò´¶¿À·Ð³èư¤Îж¿Ê¤Ë´ØÍ¿¤¹¤ë°ø»Ò¤È¤·¤Æ¤Ïarterial baroreflex¡¢cardiopulmonary baroreflex¡¢metaboreflex¡¢chemoreeflex¤Î4¤Ä¤Î°µ¼õÍÆÂÎÈ¿¼Íµ¡Ç½¤¬´ØÍ¿¤·¤Æ¤¤¤ë¤ÈÊó¹ð¤µ¤ì¤Æ¤ª¤ê¡¢ËÜ»ÜÀߤˤª¤¤¤ÆÁ´¤ÆÂ¬Äê²Äǽ¤È¤Ê¤Ã¤Æ¤¤¤ë¡£¸½ºß¡¢¤³¤ì¤é¤Î°µ¼õÍÆÂÎÈ¿¼Íµ¡Ç½¤ÈMSNA¤òÍѤ¤¤ÆËýÀ­¿´ÉÔÁ´Îã¤Ë¤ª¤±¤ë¸ò´¶¿À·Ð³èưж¿Ê¤ÎÉÂÂ֤ˤĤ¤¤Æ¸¡Æ¤¤·¤Æ¤¤¤ë¡£¤µ¤é¤Ë¡¢ACEÁ˳²Ìô¡¢AngIIÙɹ³Ìô¤Ê¤É¤Î¸ò´¶¿À·Ð³èư¤ËÂФ¹¤ë±Æ¶Á¤òÈæ³Ó¸¡Æ¤Ãæ¤Ç¤¢¤ë¡£

£´¡¥³Ë°å³Ø¤òÍѤ¤¤¿´§Æ°Ì®¼À´µ¤Ë¤ª¤±¤ë¿´¶ÚÞõή¤Ë´Ø¤¹¤ë¸¦µæ
¡¡³Ë°å³Ø¤òÍѤ¤¤¿¿´¶ÚÞõή¥¤¥á¡¼¥¸¥ó¥°¤Ï·ì´É¤±Æ¤Ç¤Ïɾ²Á¤Ç¤­¤Ê¤¤¿´¶ÚÈù¾®½Û´Ä¤òÈ󿯽±Åª¤Î¤Ëɾ²Á²Äǽ¤Ç¤¢¤ë¡£µÞÀ­¿´¶Ú¹¼ºÉ¾É¤ËÂФ¹¤ë´§Æ°Ì®·ì¹ÔºÆ·ú½Ñ¸å¤Î¿´¶ÚÈù¾®½Û´Ä½ý³²¤ÎÄêÎÌŪɾ²ÁË¡¤ò³ÎΩ¤·¤¿¡£²Ã¤¨¤Æ¡¢¿´¶ÚÈù¾®½Û´Ä½ý³²¤ËÂФ¹¤ëverapamil¤ÎÍ­¸úÀ­¤ò¾ÚÌÀ¤·¤¿¡£ºÇ¶á³«È¯¤µ¤ì¤¿¿´ÅÅ¿ÞÆ±´üSPECT¤òÍѤ¤¤ë¤³¤È¤Ë¤è¤ê
¡¡(1)¿´¶Ú¹¼ºÉ¸å¤Î·ìή-¼ý½ÌЪΥ(Stunned myocardium)¤Î¸¡½Ð¡¢
¡¡(2)ºÆÞõή¸å¤Î¶É½ê¿´µ¡Ç½²óÉü¤Ë¤ª¤±¤ë»Ä¸¿´¶Ú·ìή¤Î´ØÍ¿¤òÌÀ¤é¤«¤Ë¤·¤Æ¤¤¤¯¡£

£µ. ¿´¶ÚÈù¾¯½Û´Ä¤ÎºÆÀ¸¤Èɾ²Á
¡¡Ä¶²»ÇȤ±ÆºÞ¤Î³«È¯¡¢¿´¥¨¥³¡¼ÁõÃ֤βþÎɤˤè¤ê¡¢Ä¶²»ÇȤ±ÆºÞ¤ò·ÐÀÅ̮ŪÅêÍ¿¤¹¤ë¤³¤È¤Ë¤è¤Ã¤Æ¤â¿´¶Ú¥³¥ó¥È¥é¥¹¥È¥¨¥³¡¼¤¬²Äǽ¤È¤Ã¤¿¡£·ÐÀÅÌ®¿´¶Ú¥³¥ó¥È¥é¥¹¥È¥¨¥³¡¼(MCE)»£Áü¤Î»êŬ¾ò·ï¤ÈÎ×¾²Åª°ÕµÁ¤ÏÌÀ¤é¤«¤Ë¤Ê¤Ã¤Æ¤¤¤Ê¤¤¡£µÞÀ­¿´¶Ú¹¼ºÉËýÀ­´ü¤ËMCE¤ò»Ü¹Ô¤·¡¢¿´¶ÚÈù¾®½Û´Ä¾ã³²¤È¿´µ¡Ç½²þÁ±¡¦º¸¼¼ºÆ¹½ÃۤδØÏ¢¤ò¸¡Æ¤Ãæ¤Ç¤¢¤ë¡£¤Þ¤¿¡¢µõ·ìÀ­¿´¼À´µ¤ËÂФ¹¤ë¹ü¿ñºÙ˦°Ü¿¢¤Ë¤è¤ë¿·À¸·ì´É¤ÎÄêÎÌŪɾ²Á¤ò£ÍCE¤òÍѤ¤¤Æ¤ò¸¡Æ¤Ãæ¤Ç¤¢¤ê¡¢¤½¤Î·ë²Ì¤Î°ìÉô¤òÊó¹ð¤·¤¿¡£¤µ¤é¤Ë¡¢Ä¶²»ÇȤ±ÆºÞÅêÍ¿²¼¤Ë¶¯ÅÙ¤ÎͲ»ÇȾȼͤò¹Ô¤¦¤Èbioeffect¤Ë¤è¤êÌÓºÙ·ì´É¤¬Ç˲õ¤µ¤ì¤ë»ö¤¬ÌÀ¤é¤«¤È¤Ê¤Ã¤Æ¤­¤¿¡£¤³¤Îbioeffect¤òÍøÍѤ·MCE¤Ë¤è¤ëdrug-delivery, cell- delivery¤Î´ðÁø¡Æ¤¤ò³«»Ï¤·¤Æ¤¤¤ë¡£

£¶¡¥¿´¶ÚÁÈ¿¥À­¾õ¤È¿´µ¡Ç½¤ÎÈ󿯽±ÅªÉ¾²Á
¡¡¹¼ºÉ¿´¶Ú¤Ë¤ª¤±¤ë¿´¶ÚÆâËì³°Ë즤ÎÁÈ¿¥À­¾õ¤ÎÊѲ½¤¬º¸¼¼·ÁÂÖ°Ý»ý¤ËµÚ¤Ü¤¹±Æ¶Á¤ÏÌÀ¤é¤«¤Ë¤µ¤ì¤Æ¤¤¤Ê¤¤¡£¿´¶ÚIntegrated backscatter (IBS)¤Ë¤è¤ê¡¢¿´¶ÚÆâË즡¦³°Ë즤Îviability¤¬¸ÄÊ̤˲òÀϲÄǽ¤È¤Ê¤Ã¤¿¡£½é²ó¿´¶Ú¹¼ºÉ¤Î¿´¶ÚÆâË즤ȳ°Ë즤ÎIBS¤òµ­Ï¿¤·¡¢¤½¤ÎÊÑÆ°Î̤ÈÊÑÆ°¥Ñ¥¿¡¼¥ó¤ò²òÀϤ·¡¢¿´¶ÚÆâË즤ȳ°Ë즤ÎIBS¤Èº¸¼¼·ÁÂ֤ȤδØÏ¢¤Ë¤Ä¤¤¤Æ¸¡Æ¤Ãæ¤Ç¤¢¤ê¡¢¤½¤Î·ë²Ì¤Î°ìÉô¤òÊó¹ð¤·¤¿¡£¤Þ¤¿¡¢¿´³°Ëì»éËÃÄÀÃ夬¿´µ¡Ç½¤ËµÚ¤Ü¤¹±Æ¶Á¤Ï¸¡Æ¤¤µ¤ì¤Æ¤¤¤Ê¤¤¡£MRI¡¢¿´¥¨¥³¡¼¿Þ¤òÍѤ¤¤Æ¿´³°Ëì»éËäÎÄêÎÌɾ²Á¤ò¹Ô¤¤¡¢¿´³°Ëì»éËÃÄÀÃ夬º¸¼¼³Èĥǽ¤Ë¤ª¤è¤Ü¤¹±Æ¶Á¤ò¸¡Æ¤Ãæ¤Ç¤¢¤ë¡£¤µ¤é¤Ë»éËÃÄÀÃå·²¤Î¿´¶ÚÁÈ¿¥À­¾õ¿ÇÃǤòIBS¤Ë¤Æ²òÀϤ·fatty heart ¤Î³µÇ°¤ò³ÎΩ¤¹¤ë¤³¤È¤òÌÜŪ¤È¤·¤Æ¸¡Æ¤¤ò²Ã¤¨¤Æ¤¤¤ë¡£

£·¡¥½Û´Ä´ïÎΰè¤Ë¤ª¤±¤ë´Ñ·ìŪ¸¡ººË¡¤ª¤è¤Ó¼£ÎÅË¡¤Ë´Ø¤¹¤ë¸¡Æ¤
¡¡´§Æ°Ì®¼À´µ¤òÂоݤȤ·¡¢´§Æ°Ì®¹Å²½¡¢·ÐÈéŪ´§Æ°Ì®·ÁÀ®½Ñ(PTCA)¸å¤ÎºÆ¶¹ºõ¤ò¥Æ¡¼¥Þ¤ËÎ×¾²¸¦µæ¤ò¹Ô¤Ã¤Æ¤¤¤ë¡£¼ç¤ËÄêÎÌŪ´§Æ°Ì®²òÀϤäðôư̮ÆâͲ»Çȸ¡ºº¤«¤éÆÀ¤é¤ì¤¿½ô»ØÉ¸¤ò¤â¤È¤Ë°Ê²¼¤Î¤è¤¦¤Ê¸¡Æ¤¤ò¹Ô¤¤¡¢°ìÉô¤Î·ë²Ì¤òÊó¹ð¤·¤¿¡£
¡¡¡¡1)StentÆâºÆ¶¹ºõ¤Ë´Ø¤ï¤ë½ô°ø»Ò(vWF¡¢ACE°äÅÁ»Ò¿·¿¡¢¥Ð¥¤¥ª¥Ô¥ê¥ó)¤Î¸¡Æ¤
¡¡¡¡2)Stent¸å¤Î°¡µÞÀ­´§Êĺɤ˴ؤï¤ë¶Å¸ÇÀþÍÏ·Ï¤ÎÆ°Â֤˴ؤ¹¤ë¸¡Æ¤
¡¡¡¡3)´§·ì¹ÔºÆ·ú¤¬¿´¶ÚViability¤ª¤è¤Ü¤¹±Æ¶Á

£¸¡¥½Û´Ä´ï¼À´µ¤Î¥Ç¡¼¥¿¥Ù¡¼¥¹¹½ÃÛ
¡¡Evidence-based Medicine¤ÎÉáµÚ¤Ëȼ¤¤¡¢½¾Íè¤Î¥á¥«¥Ë¥º¥à¤Î¤ß¤Ë´ð¤Å¤¯°åÎŤè¤ê¡¢»àË´¤Ê¤É´µ¼Ô¤Ë¤È¤Ã¤Æ½ÅÍפÊoutcome¤ò¼ÂºÝ¤Ë¸º¾¯¤µ¤»¤ë»ö¤¬¾ÚÌÀ¤µ¤ì¤¿°åÎŤ¬½ÅÍ׻뤵¤ì¤Æ¤­¤Æ¤¤¤ë¡£¤½¤Î¤¿¤á¤Î¥Ç¡¼¥¿¥Ù¡¼¥¹¤È¤·¤ÆµÞÀ­¿´¶Ú¹¼ºÉ¤Ë¤è¤ë»àË´¡¢Ã×»àÀ­ÉÔÀ°Ì®¤Ë¤è¤ë»àË´¡¢¿´Ë¼ºÙư¤Ëȼ¤¦·ìÀòºÉÀò¾É¤Îȯ¾É¡¢Brugada¾É¸õ·²¤Îͽ¸å¤Ê¤É¤Î½Û´Ä´ï¼À´µ¤Ë¤ª¤±¤ë½ÅÍפʴµ¼Ôoutcome¤Ë¤Ä¤¤¤Æ¤Î¥Ç¡¼¥¿¥Ù¡¼¥¹¤ò¹½ÃÛ¤·¡¢°ìÉô¤Î·ë²Ì¤òÊó¹ð¤·¤¿¡£

£¹¡¥Ç¾À­ÍøÇ¢¥Ú¥×¥Á¥É(BNP)¤ÎÎ×¾²±þÍѤˤĤ¤¤Æ¤Î¸¡Æ¤
¡¡·ìÞùǾÀ­ÍøÇ¢¥Ú¥×¥Á¥É(BNP)Ãͤϡ¢¿´ÉÔÁ´¤Î¥Þ¡¼¥«¡¼¤È¤·¤Æ¹­¤¯Î×¾²±þÍѤµ¤ì¤Æ¤¤¤ë¤¬¡¢Î×¾²½ê¸«¤È¤ÎÉÔ°ìÃפ⤷¤Ð¤·¤Ðǧ¤á¤é¤ì¤ë¡£BNPÃͤÎÎ×¾²±þÍѤˤĤ¤¤Æ¡¢¤½¤ÎÍ­¸úÀ­¤È¸Â³¦¤Ë¤Ä¤¤¤Æ³Æ¼ï¤Î½Û´Ä´ï¼À´µ¤Ë¤Æ¸¡Æ¤¤·¡¢°ìÉô·ë²Ì¤òÊó¹ð¤·¤¿¡£¤Þ¤¿¡¢¿´Ë¼À­BNP¤È¿´¼¼À­BNP¤È¤Îº¹¤Ë¤Ä¤¤¤Æ¤â¸¡Æ¤Ãæ¤Ç¤¢¤ë¡£

ÆâʬÈ硦Âå¼Õ
1. ÆâʬÈç
¡¡¡¡ÆâʬÈ硦¹Ã¾õÁ£³°Íè¡¢ÆâʬÈ硦Âå¼Õ³°Íè¤Ç¡¢¹Ã¾õÁ£¼À´µ¤ò¤Ï¤¸¤á¤È¤¹¤ë¼ï¡¹¤ÎÆâʬÈ硦Âå¼Õ¼À´µ´µ¼Ô¤Î¿ÇÎŤò¹Ô¤¦¤È¶¦¤Ë¡¢¤³¤ì¤é¤ÎÎ×¾²Åª¤Ê¤é¤Ó¤Ë¼Â¸³Åª¸¦µæ¤ò¹Ô¤Ã¤Æ¤¤¤ë¡£
¡¡ ¡¡¹Ã¾õÁ£¥Û¥ë¥â¥óºîÍÑȯ¸½¤Ëɬ¿Ü¤Î¹ÚÁǤǤ¢¤ë1·¿µÚ¤Ó2·¿Ã¦¥è¡¼¥É¹ÚÁǤΰäÅÁ»Òȯ¸½Ä´Àᵡ½ø¤ò¥Ò¥ÈµÚ¤Ó¥Þ¥¦¥¹¤ä¥é¥Ã¥È¤Î¼ï¡¹Â¡´ï¤òÍѤ¤¤Æ¸¦µæ¤·¤Æ¤¤¤ë¡£ÆÃ¤Ë¡¢¥Ò¥È¹Ã¾õÁ£¤Ç¤Ï¡¢¥é¥Ã¥È¤È°Û¤Ê¤ê¡¢£±·¿¤Î¤ß¤Ê¤é¤º¡¢£²·¿Ã¦¥è¡¼¥É¹ÚÁǤâȯ¸½¤·¤Æ¤¤¤ë¤³¤È¤òÌÀ¤é¤«¤Ë¤·¤¿¡£¤½¤·¤Æ¡¢¥Ò¥È¹Ã¾õÁ£¤Î£±·¿¤È£²·¿¤ÎËܹÚÁÇ¤Ë¤ÏÆÈ¼«¤Îȯ¸½Ä´Àᵡ¹½¤¬¤¢¤ê¡¢À¸ÂΤιþõÁ£¥Û¥ë¥â¥ó³èÀ­²½¤Ë¤³¤ì¤é¤¬¶¨Ä´¤·¤Æ´ØÍ¿¤·¤Æ¤¤¤ë¤³¤È¤òÊó¹ð¤·¤¿¡£¹¹¤Ë¡¢¥Ò¥ÈÂçÆ°Ì®·ì´ÉÊ¿³ê¶ÚºÙ˦¤Ë2·¿Ã¦¥è¡¼¥É¹ÚÁdzèÀ­µÚ¤ÓmRNA¤¬Â¸ºß¤¹¤ë¤³¤È¤ò¼¨¤·¡¢ËܹÚÁǤ¬·ì°µ¤Ê¤É¤Ë¤â´ØÍ¿¤·¤Æ¤¤¤ë²ÄǽÀ­¤ò¼¨¤·¤¿¡£ËܹÚÁÇȯ¸½Ä´Àᵡ½ø¤ÎɾºÙ¤Ë¤Ä¤¤¤Æ¸¦µæÃæ¤Ç¤¢¤ë¡£¤Þ¤¿¡¢°­À­´ãµåÆÍ½Ð¾É¤Ë¤Ä¤¤¤Æ¡¢Î×¾²Åª¤Ë¥¹¥Æ¥í¥¤¥É¥Ñ¥ë¥¹ÎÅË¡¤ä¾È¼ÍÎÅË¡¤ò¹Ô¤¦¤È¶¦¤Ë¡¢¤½¤ÎÉÂÂÖ¤ò¸¦µæ¤·¤Æ¤¤¤ë¡£

2. ÅüÇ¢ÉÂ
¡¡ÅüǢɳ°Íè¤ò¼õ¿Ç¤¹¤ë´µ¼Ô¿ô¤Ïǯ¡¹Áý²Ã¤·¤Æ¤ª¤ê¡¢¤Þ¤¿¡¢Æþ±¡¤Ç¤Ï¡¢·ìÅü¥³¥ó¥È¥í¡¼¥ë¤äÅüǢɶµ°éÌÜŪ´µ¼Ô¤«¤é¡¢½Å¾É¹çÊ»¾É¤òÍ­¤¹¤ë´µ¼Ô¤Î¼£ÎŤޤÇÉý¹­¤¤´µ¼Ô¤Î¿ÇÎŤËÂбþ¤·¤Æ¤¤¤ë¡£ÅüǢɿÇÎŤκǶá¤ÎÆÃħ¤Ï¡¢¼ï¡¹¤Î¥¤¥ó¥¹¥ê¥óÀ½ºÞ¤Ë¤è¤ë¸·³Ê¤Ê·ìÅü¥³¥ó¥È¥í¡¼¥ëË¡¤ä¿·¤·¤¤ÆâÉþ¤ÎÌôʪ¼£ÎŤ¬¼ï¡¹³«È¯¤µ¤ì¤Æ¤­¤¿¤³¤È¤Ç¤¢¤ë¡£¤³¤ì¤é¤Î´µ¼Ô¤òÂоݤˡ¢¸½ºß¤ª¤â¤ËÅüǢɴÉÍýµÚ¤Ó¹çÊ»¾É¤Îȯ¾É¡¦¿ÊŸÁ˻ߤΤ¿¤á¤ÎÎ×¾²Åª¸¦µæ¤ò¹Ô¤Ã¤Æ¤¤¤ë¡£­µ·¿ÅüǢɤˤª¤±¤ë¼À´µ´¶¼õÀ­HLA¥Ï¥×¥í¥¿¥¤¥×¤Î²òÀϤòÊó¹ð¤·¤¿¡£¤Þ¤¿¡¢ÅüǢɤˤª¤±¤ë·ì¾®Èĵ¡Ç½Ð¶¿Ê¤Î¥á¥«¥Ë¥º¥à¤Î²òÀϤȹçÊ»¾É¤Ø¤Î´ØÏ¢¤Ë¤Ä¤­¸¡Æ¤¤·¤Æ¤ª¤ê¡¢Ã±µå¤ª¤è¤Ó·ì¾®ÈijèÀ­²½¥Þ¡¼¥«¡¼¤ÎưÂ֤ˤĤ¤¤ÆÊó¹ð¤·¤Æ¤¤¤ë¡£¤µ¤é¤Ë¡¢³Æ¼ïÀÜÃåʬ»Ò¤Î¬Äê (VCAM-1, ICAM-1, P-selection) ¤ò¹Ô¤¤¡¢¹³·ì¾®ÈĺÞÅêÍ¿¤Î¸ú²Ì¤Ë¤Ä¤¤¤ÆÎ×¾²Åª¸¦µæ¤ò¹Ô¤Ê¤Ã¤Æ¤¤¤ë¡£

3¡¥ÅüǢɤδðÁø¦µæ
¡¡ÅüÇ¢ÉÂʬÌî¤Ç¤Î´ðÁø¦µæ¤È¤·¤Æ¤Ï¡¢ÅüÇ¢ÉÂÀ­¹çÊ»¾É¤ÎÀ®°ø¤òÌÀ¤é¤«¤Ë¤¹¤ë¤³¤È¤òÌÜŪ¤Ë¸¦µæ¤ò¤ª¤³¤Ê¤Ã¤Æ¤¤¤ë¡£¤³¤ì¤Þ¤ÇÅüÇ¢ÉÂÀ­¹çÊ»¾É¤Î¿ÊŸ°ø»Ò¤È¤·¤Æ¤Ï¥Ý¥ê¥ª¡¼¥ë·ÏÂå¼Õ¡¢£Ã¥­¥Ê¡¼¥¼³èÀ­¡¢Åü²½ÃÁÇò¤ª¤è¤Ó»À²½¥¹¥È¥ì¥¹¤Ê¤É¤Î´ØÍ¿¤¬Êó¹ð¤µ¤ì¤Æ¤¤¤ë¡£¸½ºß²æ¡¹¤ÏÅü²½ÃÁÇò¤Î¼õÍÆÂΤΤҤȤĤǤ¢¤ëRAGE (receptor for advanced glycation endproducts) ¤Î¥·¥°¥Ê¥ëÅÁãÍͼ°¤Î²òÌÀ¤ª¤è¤Ó¡¢¤½¤Î¿·µ¬¥ê¥¬¥ó¥É¤Ç¤¢¤ëS100´ØÏ¢ÃÁÇò¤ÎÅüÇ¢ÉÂÀ­¹çÊ»¾É¤Ø¤Î´ØÍ¿¤ò¡¢Ê¬»ÒÀ¸Êª³ØÅª¼êË¡¤òÍѤ¤¸¡Æ¤¤·¤Æ¤¤¤ë¡£

¿Õ¡¡Â¡¡¦·ì±ÕÆ©ÀÏ
1.¡¡¥Æ¥¤¥é¡¼¥á¥¤¥É°åÎŤò¤á¤¶¤·¤¿ÀèÅ·À­¿ÕÀ­Ç¢Êø¾É²È·Ï¤Î°äÅÁ»Ò²òÀÏ
¡¡ÀèÅ·À­¿ÕÀ­Ç¢Êø¾É¤ÏÀèŷŪ¤Ê¿ÕÇ¢ºÙ´É¤Ç¤Î¥Ð¥½¥×¥ì¥·¥ó(AVP)ÉÔ±þÀ­¤Ë¤è¤êǢǻ½Ì¾ã³²¤òµ¯¤³¤¹¼õÍÆÂΰ۾ï¾É¤Ç¤¢¤ë¡£»äã¤ÏËÜË®¤Ë¤ª¤¤¤Æ10²È·Ï¤ÎAVP¼õÍÆÂΰäÅÁ»ÒÇÛÎó¤ò¸¡Æ¤¤·¡¢É°ø¤È¤Ê¤ë°äÅÁ»Ò°Û¾ï¤ò½é¤á¤ÆÊó¹ð¤·¤¿¡£¤µ¤é¤ËCHOºÙ˦¤ËÄê¾ïȯ¸½¤µ¤»¤ë¤³¤È¤Ë¤è¤êµ¡Ç½°Û¾ï¤òºÆ¸½¤·È¯¾É¤Îʬ»Òµ¡¹½¤ò²òÌÀ¤·¤¿¡£

2.­¡¿ÕÀ¸¸¡Áü¤«¤é¤ß¤¿¿Õ±ê¡¦¥Í¥Õ¥í¡¼¥¼¾É¸õ·²¤Î¼£ÎŤª¤è¤Óͽ¸å¤Ë±Æ¶Á¤¹¤ë°ø»Ò¤Î¸¡Æ¤
¡¡¿Õ¼À´µ¤Ë¤ª¤±¤ëÎ×¾²Åª¸¦µæ¤È¤·¤Æ¡¢¤³¤ì¤Þ¤ÇËìÀ­¿Õ¾É¤Î¼£ÎŤª¤è¤Óͽ¸å¤Ë´Ø¤¹¤ë°ø»Ò¤Ë¤Ä¤¤¤Æ¿ÕÁÈ¿¥Áü¤«¤é¤Î¸¡Æ¤¤ò¹Ô¤Ã¤Æ¤­¤¿¡£º£¸å¤Ï¡¢¤ï¤¬¹ñ¤ÇºÇ¤â¿¤¤¸¶È¯À­»åµåÂοձê¤Ç¤¢¤ëIgA¿Õ¾É¤Î¿ÕÀ¸¸¡ÁÈ¿¥¤â¸¡Æ¤¤·¤Æ¤¤¤¯Í½Äê¤Ç¤¢¤ë¡£´ðÁÃʬÌî¤Ç¤Ï¿ÕÀþ°Ý²½¤Ë¤ª¤±¤ë¥á¥µ¥ó¥®¥¦¥à¤ª¤è¤Ó¿ÕÇ¢ºÙ´ÉºÙ˦¤ËÂФ¹¤ë¥¢¥ó¥¸¥ª¥Æ¥ó¥·¥ó­¶¤ÎºîÍѵ¡½ø¡¢ÆÃ¤ËÀ®Ä¹°ø»Ò¤ò²ð¤·¤¿ºÙ˦ÆâÅÁ㵡¹½¤ò¼ç´ã¤È¤·¤¿¸¦µæ¤ò¹Ô¤Ã¤¿¡£Î×¾²Ê¬Ìî¤Ç¤Ï¡¢ËýÀ­¿ÕÉÔÁ´¤Î·ì°µ´ÉÍý¤Ë¤ª¤±¤ë¦Á¼×ÃÇÌô¤Î°ÌÃÖÉÕ¤±¤Ë´Ø¤¹¤ë¸¡Æ¤¤Ê¤é¤Ó¤Ë¥Ñ¥ë¥Ü¥¦¥£¥ë¥¹¤Ë¤è¤ëµÞÀ­¿Õ±ê¤ÎÎ×¾²ÅªÆÃħ¤Ë¤Ä¤¤¤Æ²òÀϤ·¤¿¡£
¡¡­¢Ç¢ºÙ´ÉºÙ˦¤Ë¤ª¤±¤ëTGF-¦Â¤ÎºÙ˦ÆâÅÁ㵡¹½ ¿¤¯¤ÎËýÀ­¿Õ¼À´µ¤Î¿ÊŸ¤ÏÇ¢ºÙ´É´Ö¼ÁÉÂÊѤˤè¤ë¡£¤½¤Îkey molecule¤Ç¤¢¤ëTGF-¦Â¤Ë¤Ä¤¤¤Æ¡¢Ç¢ºÙ´ÉºÙ˦¤Ë¤ª¤±¤ëºÙ˦Æâ¾ðÊóÅÁ㵡½ø¤ò¸¡Æ¤¤·¤Æ¤¤¤ë¡£

3. ·ì±ÕÆ©ÀÏ
¡¡Æ©Àϼ¼¤Ç¤Ï¡¢Âè2Æâ²Ê¤Î´µ¼Ô¤ò¤Ï¤¸¤á¡¢¼ï¡¹¹çÊ»¾É¤òµ¯¤³¤·¤ÆÆþ±¡¤·¤¿±¡Æâ³Æ²Ê¤Î´µ¼Ô¤òÆ©ÀϤ·¤Æ¤¤¤ë¡£¤Þ¤¿¡¢²È²À­¹â¥³¥ì¥¹¥Æ¥í¡¼¥ë·ì¾É´µ¼Ô¤ä¿Õ¼À´µ´µ¼Ô¤ËLDL¥¢¥Õ¥§¥ì¡¼¥·¥¹¤ò»Ü¹Ô¤·¤¿¤ê¡¢¼ï¡¹¤Î·ìÞù¸ò´¹ÎÅË¡¤â¹Ô¤Ã¤Æ¤¤¤ë¡£»ý³ʢËìÆ©ÀÏ(CAPD)´µ¼Ô¤âÁý²Ã¤·¤¿¡£·ì±ÕÆ©ÀÏ´µ¼Ô¤ÎƳÆþ´ü¡¢µÚ¤ÓËýÀ­´ü¤Î¹çÊ»¾É¤Ë¤Ä¤¤¤Æ¡¢ÆÃ¤Ë¡¢Æ©ÀÏ´µ¼Ô¤Î¹Ã¾õÁ£µ¡Ç½¤ä·ìÃæ¹Ã¾õÁ£¥Û¥ë¥â¥ó°Û¾ï¡¢Éû¹Ã¾õÁ£°Û¾ï¤Ê¤ÉÆâʬÈç°Û¾ï¤Î´ØÏ¢¤Ë¤Ä¤¤¤Æ¸¡Æ¤¤·¤Æ¤¤¤ë¡£¤Þ¤¿¡¢ÅüǢɿվɤÎȯ¾É¤È¿ÊŸ¤Ë´Ø¤¹¤ë¸¦µæ¤ò¹Ô¤Ã¤Æ¤¤¤ë¡£¹¹¤Ë¡¢¶¹¿´¾É¡¦¿´¶Ú¹¼ºÉ¤Ê¤É¤Î´§Æ°Ì®¼À´µ¹çÊ»¤Ë´Ø¤·¤Æ¡¢Â¿¤¯¤Î´µ¼Ô¤òÂоݤȤ·¤ÆÎ×¾²Åª¸¦µæ¤ò³¤±¤Æ¤¤¤ë¡£

¹â·ì°µ¡¦Æ°Ì®¹Å²½¡¦Âå¼Õ
£±. ºÙ˦°Ü¿¢¡¦°äÅÁ»Ò¼£ÎŤˤè¤ëư̮¹Å²½À­¿´·ì´Éɤˤª¤±¤ë·ì´É¿·À¸¤òÌÜŪ¤È¤·¤¿ºÆÀ¸°åÎÅ ¡¡¹ü¿ññ³ËµåºÙË¦Ãæ¤Ë¤Ï·ì´ÉÆâÈéÁ°¶îºÙ˦¤¬Â¸ºß¤·¡¢¿´¶Ú¤ä²¼»è¹ü³Ê¶Ú¤Îµõ·ìÁÈ¿¥¤Ë¤ª¤¤¤Æ¤³¤ÎÆâÈéÁ°¶îºÙ˦¤Ï·ì´É¿·À¸¤òͶƳ¤¹¤ë¤³¤È¤ò´ðÁü¸³¤è¤êÌÀ¤é¤«¤Ë¤·¤¿¡£´ØÀ¾°åÂçÎÑÍý°Ñ°÷²ñ¤Î¾µÂú¤òÆÀ¤Æ¡¢2000ǯ7·î14Æü¤Ë²¼»èÊĺÉÀ­Æ°Ì®¹Å²½¾É¤Î´µ¼Ô¤µ¤ó¤Ë¡¢¼«¸Ê¹ü¿ññ³ËºÙ˦¤ò°Ü¿¢¤·Í­¸ú¤Ê·ì´É¿·À¸¡¦¼«³Ð¾É¾õ¤Î²þÁ±¤òǧ¤á¤¿¡£°Ê¸å¡¢45¿Í¤Îµõ·ì»è´µ¼Ô¤µ¤ó¤Ë¼Â»Ü¤·¤¿¡£2001ǯ12·î19Æü¤Ë½Å¾Éµõ·ìÀ­¿´¼À´µ¾ÉÎã¤Ë¼Â»Ü¤·¤¿¡£¿´Çï½ÐÎ̤¬Áý²Ã¤·¡¢¶»Äˤâ¾Ã¼º¤·¤¿¡£¹ü¿ññ³Ëµå°Ü¿¢¤òÍѤ¤¤¿·ì´É¿·À¸¼£ÎŤÏÁ´¹ñ22Âç³ØÉ±¡¤ÇºÎÍѤµ¤ì¡¢»ä㤬³ÎΩ¤·¤¿¥×¥í¥È¥³¡¼¥ë¤¬ºÎÍѤµ¤ì¤Æ¤ª¤ê¡¢º£¸å¤³¤ÎºÆÀ¸°åÎŤÎÃæ¿´»ÜÀߤȤ·¤Æµ¡Ç½¤¹¤ë¤È¹Í¤¨¤é¤ì¤ë¡£

£²¡¥°äÅÁ»Ò¹©³Ø¤òÍѤ¤¤¿·ì´ÉºîƯÀ­Êª¼Á¡Ê¥¢¥ó¥¸¥ª¥Æ¥ó¥·¥óII¡¦¥«¥Æ¥³¥é¥ß¥ó¡ËºîÍѤÎʬ»Ò¡¦¸ÄÂÎ¥ì¥Ù¥ë¤Ç¤Î²òÀϤȼõÍÆÂΤÎȯ¸½Ä´Àá
¡¡°äÅÁ»Ò¹©³Ø¤òÍѤ¤¤Æ·ì´ÉºîƯÀ­Êª¼Á¼õÍÆÂΤηì´ÉÊ¿³ê¶ÚÆÃ°ÛŪ¤¢¤ë¤¤¤Ï¿´¶ÚÆÃ°ÛŪ²á¾êȯ¸½¥È¥é¥ó¥¹¥¸¥§¥Ë¥Ã¥¯¥Þ¥¦¥¹¤òºîÀ½¤·¡¢¸ÄÂÎ¥ì¥Ù¥ë¤Ç¤Î¿´·ì´ÉºîÍѤòÌÀ¤é¤«¤Ë¤·¤Æ¤­¤¿¡£

£³.¡¡¥Æ¥¤¥é¡¼¥á¥¤¥É°åÎŤò¤á¤¶¤·¤¿ÀèÅ·À­¿ÕÀ­Ç¢Êø¾É²È·Ï¤Î°äÅÁ»Ò²òÀÏ
¡¡ÀèÅ·À­¿ÕÀ­Ç¢Êø¾É¤ÏÀèŷŪ¤Ê¿ÕÇ¢ºÙ´É¤Ç¤Î¥Ð¥½¥×¥ì¥·¥ó(AVP)ÉÔ±þÀ­¤Ë¤è¤êǢǻ½Ì¾ã³²¤òµ¯¤³¤¹¼õÍÆÂΰ۾ï¾É¤Ç¤¢¤ë¡£»äã¤ÏËÜË®¤Ë¤ª¤¤¤Æ10²È·Ï¤ÎAVP¼õÍÆÂΰäÅÁ»ÒÇÛÎó¤ò¸¡Æ¤¤·¡¢É°ø¤È¤Ê¤ë°äÅÁ»Ò°Û¾ï¤ò½é¤á¤ÆÊó¹ð¤·¤¿¡£¤µ¤é¤ËCHOºÙ˦¤ËÄê¾ïȯ¸½¤µ¤»¤ë¤³¤È¤Ë¤è¤êµ¡Ç½°Û¾ï¤òºÆ¸½¤·È¯¾É¤Îʬ»Òµ¡¹½¤ò²òÌÀ¤·¤¿¡£

¡Ô¸¦µæ¶ÈÀÓ¡Õ

¸¶¡¡¡¡Ãø

  1. Tsuka Y, Sugiura T, Hatada K, Nakamura S, Yuasa F and Iwasaka T (2001)
    Clinical significance of ST-segment elevation in lead V1 in patients with acute inferior wall Q-wave myocardial infarction.
    Am Heart J 141:615-620
  2. Hamada S, Nakamura S, Sugiura T, Nishiue T, Watanabe J, Hatada K, Miyoshi H, Baden M and Iwasaka T (2001)
    Accuracy of technetium-99m tetrofosmin myocardial perfusion imaging in the detection of spontaneous recanalization in patients with acute anterior myocardial infarction.
    Eur J Nucl Med 28:326-333
  3. Hamada S, Nishiue T, Nakamura S, Sugiura T, Kamihata H, Miyoshi H, Imuro Y and Iwasaka T (2001)
    TIMI frame count immediately after primary coronary angioplasty as a predictor of functional recovery in patients with TIMI 3 reperfused acute myocardial infarction.
    J Am Coll Cardiol 38:666-671
  4. Watanabe J, Nakamura S, Sugiura T, Takehana K, Hamada S, Miyoshi H, Saito D, Hatada K, Kurihara H, Baden M and Iwasaka T (2001)
    Early identification of impaired myocardial reperfusion with serial assessment of ST segments after percutaneous transluminal coronary angioplasty during acute myocardial infarction.
    Am J Cardiol 88:956-959
  5. Hatada K, Sugiura T, Kamihata H, Nakamura S, Takahashi N, Yuasa F and Iwasaka T (2001)
    Clinical significance of coronary flow to the infarct zone before successful primary percutaneous transluminal coronary angioplasty in acute myocardial infarction.
    Chest 120:1959-1963
  6. Sugiura T, Yamasaki F, Hatada K, Nakamura S and Iwasaka T (2001)
    Correlates of bundle-branch block in patients undergoing primary angioplasty for acute myocardial infarction.
    Clin Cardiol 24:770-774
  7. Tokunaga S, Tsuji H, Nishiue T, Yamada K, Miyasaka Y, Saitou D and Iwasaka T (2001)
    Lower mortality in patients with the DD genotype of the Angiotensin - converting enzyme gene after acute myocardial infarction.
    Acta Cardiolol 56:351-355
  8. Miyasaka Y, Tsuji H, Yamada K, Tokunaga S, Saito D, Imuro Y, Matsumoto N and Iwasaka T (2001)
    Prevalence and mortality of the Brugada-type electrocardiogram in one city in Japan.
    J Am Coll Cardiol 38:771-774
  9. Miyoshi H, Takayama Y, Tamura T,Kitashiro S,Izuoka T, Saito D, Imuro Y and Iwasaka T(2001)
    Regional myocardial function at the papillary muscle Insertion site.
    Jpn J Physiol 51:109-114
  10. Takehana K, Sugiura T, Nagahama Y, Hatada K,Okugawa S and Iwasaka T (2000)
    Cardiovascular response to combined ststic-dynamic exercise of patients with myocardial infarction.
    Coron Artery Dis 11:35-40
  11. Kamihata H, Matsubara H, Nishiue T, Fujiyama S, Tsutsumi Y, Ozono R, Masaki H, Mori Y, Iba O, Tateishi E, Kosaki A, Shintani S,Murohara T, Imaizumi T, Iwasaka T(2001)
    Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines.
    Circulation 104:1046-1052
  12. Hara K, Morita Y, Kamihata H, Iwasaka T and Takahashi H(2001)
    Evidence for Infection with helicobacter pylori in patients with acute myocardial infarction.
    Clin Chim Acta 313:87-94
  13. Ohyama H, Kajita H, Omori K, Takumi T, Hiramoto N,Iwasaka T and Matsuda H (2001)
    Inhibition of cardiac delayed rectifier K+ currents by an antisense oligodeoxynucleotide against lsK(minK) and over-expression of isK mutant D77N in neonatal mouse hearts.
    Eur J Physiol 442:329-335
  14. Morita Y, Takahashi H, Kamihata H, Yamamoto Y, Hara K and Iwasaka T(2001)
    Urinary excretion of biopyrrins, oxidative metabolites of bilirubin, increases after spasm provocation tests in patients with coronary spastic angina.
    Cardiology 80:243-250
  15. Fujiyama S, Matsubara H, Nozawa Y, Maruyama K, Mori Y, Tsutsumi Y, Masaki H, Uchiyama Y, Koyama Y, Nose, Iba O, Tateishi E, Ogata N. Jyo N, Higashiyama S and Iwasaka T(2001)
    Angiotensin AT1 and AT2 receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor(EGF) -Mediated EGF receptor transactivation.
    Circ Res 88:22-29
  16. Uchiyama-Tanaka Y, Matsubara H, Nozawa Y, Murasawa S, Mori Y, Kosaki A, Maruyama K, Masaki H, Shibasaki Y, Fujiyama S, Nose A, Iba O, Hasegawa T, Tateishi E, Higashiyama S and Iwasaka T (2001)
    Angiotensin II signaling and HB- EGF shedding via metalloproteinase in glomerular mesangial cells.
    Kidney Int 60: 2153-2163
  17. Mori Y, Matsubara H, Nose A, Shibasaki Y, Masaki H, Kosaki A, Ikigaki N, Fujiyama S, Tanaka-Uchiyama Y, Hasegawa T, Iba O, Tateishi E, Amano K and Iwasaka T (2001)
    Safety and availability of doxazosin in treating hypertensive patients.
    Hypertens Res 24: 359-366
  18. Shibasaki Y, Matsubara H, Nozawa Y, Mori Y, Masaki H, Kosaki A, Tsutsumi Y, Uchiyama Y, Fujiyama S, Nose A, Iba O, Tateishi E, Hasegawa T, Horiuchi M, Nahmias C and Iwasaka T (2001)
    Angiotensin II Type 2 Receptor Inhibits EGF Receptor Transactivation by Increasing Association of SHP-1 TyrosinePhosphatase
    Hypertension 38:367-372
  19. Nakagami H, Morishita R, Yamamoto K, Yoshimura S, Taniyama Y, Aoki M, Matsubara H, Kim S, Kaneda Y and Ogihara T (2001)
    Phosphorylation of p38 mitogen-activated protein kinase downstream of bax-caspase-3 pathway leads to cell death induced by high D-glucose in human endothelial cells.
    Diabetes 50:1472-1481
  20. Matsubra H(2001)
    Renin-angiotensin system in human failing hearts: message From nonmyocyte cells to myocytes.
    Circ. Res 88:861-863
  21. Fujiyama S, Matsubara H, Mori Y, Masaki H, Tsutsumi Y, Shibasaki Y, Kitabayashi I, Uchiyama Y, Iba O and Iwasaka T (2001)
    Angiotensin AT1 and AT2 Receptors Differentially Regulate Angiopoietin 2 Expression and VEGF Expression and Angiogenesis by Modulating Heparin Binding EGF-Mediated EGF Receptor Transactivation.
    Circ.Res 88:22-29
  22. Hattori R, Otani H, Moriguchi Y, Matsubara H, Yamamura T, Nakao Y, Omiya H, Osako M and Imamura H(2001)
    NHE and ICAM-1 expression in hypoxic/reoxygenated coronary microvascular endothelial cells.
    Am J Physiol Heart Circ Physiol 280:H2796-2803
  23. Imai Y, Toyoda N, Maeda A, Kadobayashi T, Wang F, Kuma K, Nishikawa M and Iwasaka T (2001)
    Type 2 iodothyronine deiodinase expression isupregulated by the protein kinase A-dependent pathway and is downregulated by the protein kinase C-dependent pathway in cultured human thyroid cells.
    Thyroid 11: 899-907
  24. Tashima S, Kimura Y and Okuda T (2001)
    Assessment of local body composition by near infrared interactance(NIR).
    Body Composition 7¡§11-13
  25. ȪÅÄ·û¸ã¡¢¿ù±ºÅ¯Ï¯¡¢ÃæÂ¼À¿»Ö¡¢±º¾å¾»Ìé¡¢´äºäÔèÆó (2001)
    ¿´¶Ú¹¼ºÉȯ¾É»þ¤Ë¤ß¤é¤ì¤ëÓÒµ¤¡¦ÓÒÅǤÎÎ×¾²Åª°ÕµÁ.
    Æü½¸Ãæ¼£ÎŰå²ñ»ï 8:97-101
  26. »³ËÜů»Ë¡¢ÃæÃ« Àµ¡¢µ®Åçϵס¢²ÏÌî·¼»Ò¡¢¿¹ÅÄ Å¯¡¢¾®»å¿Î»Ë¡¢Ë­ ¹É¡¢µÜºäÍÛ»Ò¡¢ÃæÂ¼À¿»Ö¡¢´äºäÔèÆó¡¢¿¢Â¼Ë§»Ò(2001)
    ¿´¥¨¥³¡¼¾å³ÈÄ¥·¿¿´¶Ú¾ÉÍͤÎÊѲ½¤òÍ褷¤¿ Multicentric Castleman¡Çs Disease ¤Î1Îã.
    ÆüÆâ²ñ»ï¡¡90:123-126.
  27. ÄÔ µ×»Ò¡¢°æ¾å Ű¡¢±àÆ£ÍÛ»Ò¡¢ËÌÀî¹á¿¥¡¢ÌÚ¸¶ ͵ (2001)
    Î×¾²±Ö³Ø¤òÂêºà¤È¤·¤¿¼ÂÁ©Åª¤Ê°å³ØÅý·×½èÍý±é½¬¤Î»î¤ß¤È¤½¤Îɾ²Á.
    Ê¿À®13ǯÅÙ¾ðÊó½èÍý¶µ°é¸¦µæ½¸²ñ¹Ö±éÏÀʸ½¸¡Ê¼çºÅ¡§Ê¸Éô²Ê³Ø¾Ê¡¦Ï²λ³Âç³Ø¡Ë245-248
  28. »°¹¥¹­Åµ, ÀÆÆ£Âç¼ù, ȪÅÄ·û¸ã, ¿ÀÈ«¡¡¹¨, ¿¹ÅÄ¡¡´², °Ë¼¼Í´²ð, ßÀÅÄ¿®°ì¡¢µÜºäÍÛ»Ò, ´äºäÔèÆó(2001)
    ¿´ÅÅ¿ÞÊѲ½¤ò¤È¤â¤Ê¤ï¤Ê¤¤¶»ÄËȯºî.
    ¥Ï¡Ý¥È¥Ê¡Ý¥·¥ó¥° 14:57-60
  29. ßÀÅÄ¿®°ì¡¢¾¾ËÜŵ»Ò, µÜºäÍÛ»Ò, »þ²¬¿¿Íý, ¾®¾¾¡¡¹á, ÄÍ Ë§ÌÀ¡¢¿¹ÅÄ¡¡´²,¿ÀÈ«¡¡¹¨, »³Ëܹî¹À, ÀÆÆ£Âç¼ù, »°¹¥¹­Åµ, °Ë¼¼Í´²ð, Â绳½¨É×,´äºäÔèÆó (2001)
    QRS¤¬¹­¤¤¿´Åſޤò¼¨¤¹¶»ÄËȯºî¤Î1Îã.
    ¥Ï¡Ý¥È¥Ê¡Ý¥·¥ó¥° 14:44-46
  30. ÃæÂ¼À¿»Ö¡¢ÈªÅÄ·û¸ã¡¢ÀÆÆ£Âç¼ù, »°¹¥¹­Åµ, »³Åĸ÷°ì, Åò»³ÎáÊå, ̣¼¡¡½ã,ßÀÅÄ¿®°ì¡¢´äºäÔèÆó(2001)
    99mTechnetium ¥Ô¥í¥ê¥ó»À¿´¶Ú¥·¥ó¥Á¥°¥é¥Õ¥£¤Ë¤è¤êÁá´ü³ÎÄê¿ÇÃǤ˻ê¤Ã¤¿¿´¥¢¥ß¥í¥¤¥É¡¼¥·¥¹¤Î°ìÎã.
    Osaka Heart Club 24:6-12
  31. »³ËÜů»Ë¡¢¿¹¡¡ÂÙÀ¶, ǽÀªÆØ»Ò, ¾¾¸¶¹°ÌÀ, ´äºäÔèÆó(2001)
    ¶õIJÀü¹¦¤ò¤­¤¿¤·¤¿Á´¿ÈÀ­¥³¥ì¥¹¥Æ¥í¡¼¥ëºÉÀò¾É¤Î1˶¸¡Îã.
    Lipid 11:89-94
  32. Åò»³ÎáÊå, ÅòÀõʸͺ, ɧºä¡¡À¿, ̣¼¡¡½ã, ¸µ×¢¾­Ç·, ¿ù±ºÅ¯Ï¯, ´äºäÔèÆó (2001)
    ËýÀ­¿´ÉÔÁ´¤Ë¤ª¤±¤ëÈ¿ÉüÀ­rhythmic handgrip »þ¤Î¶Ú¸ò´¹¿À·Ð³èư¤Î¸¡Æ¤.
    ¿´Â¡¡¡32:18-21
  33. ̣¼¡¡½ã, ÅòÀõʸͺ, ɧºä¡¡À¿, Åò»³ÎáÊå, ²Ï¼¹¸¹°, ßÀÅÄ¿®°ì¡¢¿ù±ºÅ¯Ï¯, ´äºäÔèÆó(2001)
    ËýÀ­¿´ÉÔÁ´¤Ë¤ª¤±¤ë±¿Æ°»þmetaboreflex¤ÈËö¾¿¸ò´¹¿À·Ð³èư¤Î¸¡Æ¤.
    ¿´Â¡ 33:95-97
  34. µÜºäÍÛ»Ò, º´µ×´Ö¹§Íº, ¾¾ËÜŵ»Ò, »þ²¬¿¿Íý, ¾®¾¾¡¡¹á, ÄÍ Ë§ÌÀ, ÀÆÆ£Âç¼ù, »°¹¥¹­Åµ, °Ë¼¼Í´²ð, ´äºäÔèÆó(2001)
    ¹âÎð½÷À­¤ÇÄã²¼¤ÈTÇÈÊ¿Äã²¼¤ò ǧ¤á¤¿°ìÎã.
    ¥Ï¡Ý¥È¥Ê¡Ý¥·¥ó¥° 14:14-16
  35. ̣¼¡¡½ã, ÅòÀõʸͺ, Åò»³ÎáÊå, ²Ï¼¹¸¹°, ´äºê¿¿²Â, ÆÁ±Ê¡¡ÃÒ, ´äºäÔèÆó(2001)
    ËÜÂÖÀ­¹â·ì°µ¾ÉÎã¤Ë¤ª¤±¤ë¥¢¥ó¥¸¥ª¥Æ¥ó¥·¥ó­¶¼õÍÆÂÎÙɹ³Ìô¤ÎÍ­ÍÑÀ­.
    Osaka Heart Club 120:6-9
  36. ÌÚ¼¡¡¾÷(2001)
    ±¿Æ°ÎÅË¡»ØÆ³´ÉÍýÎÁ¤ÎŬ±þ³ÈÂç¤Ë¤ª¤±¤ëÎ×¾²¾å¤ÎÌäÂêÅÀ
    Î×¾²±¿Æ°ÎÅË¡¸¦µæ²ñ»ï¡¡3¡§5-6
  37. ÌÚ¼¡¡¾÷¡¢´äºäÔèÆó(2001)
    ¥Ó¥¸¥å¥¢¥ë¥¹¥Æ¥Ã¥×¥¨¥¯¥µ¥µ¥¤¥º¤ÎÄê¾ï¿´Çï¿ôÍ­»ÀÁDZ¿Æ°¤Ø¤Î±þÍÑ.
    ÆüËÜ¿´Â¡¥ê¥Ï¥Ó¥ê¥Æ¡¼¥·¥ç¥ó³Ø²ñ»ï¡¡ 6¡§59-61
  38. ÇϾìÅ·¿®¡¢ÌÚ¼¡¡¾÷¡¢º´Æ£¡¡¹ë (2001)
    ±¿Æ°ÎÅË¡¤Ë¤ª¤±¤ë¥«¥¦¥ó¥»¥ê¥ó¥°²ðÆþ¥·¥¹¥Æ¥à¤Î»î¤ß.
    Î×¾²±¿Æ°ÎÅË¡¸¦µæ²ñ»ï¡¡3¡§23-29
  39. ÅÄÅ躴Ï»ҡ¢ÌÚ¼¡¡¾÷ (2001)
    ¥Ç¥¸¥¿¥ë¥«¥á¥é¤Ä¤­·ÈÂÓÅÅÏäòÍøÍѤ·¤¿ÈîËþ¤Î¿©»ö»ØÆ³.
    Î×±É 100¡§28-33

Áí¡¡¡¡Àâ

  1. ¿ù±ºÅ¯Ï¯¡¢»³ºêʸÌ÷¡¢ÃæÂ¼À¿»Ö¡¡(2001)
    Î×¾²¸¡ºº¡¡³ÆÏÀ¡§Æâ²Ê°å¤È¤·¤ÆÃΤäƤª¤¯¤Ù¤­¿·¤·¤¤¸¡ºº2. ½Û´Ä´ï·Ï¼À´µ.
    ÆüÆâ³Ø»ï¡¡90:2206-2212.
  2. ÃæÂ¼À¿»Ö¡¢ßÀÅÄ¿®°ì¡¢ÄÍ Ë§ÌÀ¡¢´äºäÔèÆó (2001)
    µÞÀ­¿´ÉÔÁ´¤Î¿ÇÃǤοʤáÊý. ½Û´Ä´ï¼À´µver.2.
    Ê̺ý°å¤Î¤¢¤æ¤ß¡¡194-196.
  3. ÄÔ¡¡µ×»Ò (2001)
    ¾ÉÎãÂоȸ¦µæ¤ÎÆÉ¤ßÊý¡¦¥Á¥§¥Ã¥¯¥ê¥¹¥È.
    EBM¥¸¥ã¡¼¥Ê¥ë 2:632-636¡¡
  4. ´äºäÔèÆó (2001)
    ·ì´É¿·À¸ÎÅË¡.
    Medical View Points 22:1
  5. ¾¾¸¶¹°ÌÀ, ¿ÀÈ«¡¡¹¨, À¾¾å¾°»Ö, Æ£»³Áí°ìϺ, ´äºäÔèÆó(2001)
    ¿´·ì´É·Ï¤ÎºÆ À¸°åÎÅ.
    Medical View Points 22:2
  6. ´äºäÔèÆó, µÜºäÍÛ»Ò, ¹âÅĸü¾È(2001)
    ÆÃ½¸¡Ö¿´ÅſޤòÆÉ¤à¡×­¶Æ¶À­PÇȤΠ¡¡ ·ÁÂ֤Ȱ۾ï1.ÇÈ·Á¡¦·ÁÂÖa.Àµ¾ï.
    Heart View 5:22-23
  7. ÅòÀõʸͺ, Åò»³ÎáÊå, ̣¼¡¡½ã, ²Ï¼¹¸¹°, ´äºê¿¿²Â, ´äºäÔèÆó(2001)
    Ϣ³ ¡¡¡¡Åª¿´Çï½ÐÎÌ¥â¥Ë¥¿¥ê¥ó¥°. ¡¡
    µßµÞ°å 25:785-788
  8. ¿ÝëÊÝÉס¢ÌÌÚ¹¨ (1999)
    ¿´¸¶À­¥·¥ç¥Ã¥¯.
    µßµÞ°å 23¡§1243-1246
  9. ¿ÀÈ«¡¡¹¨¡¢¾¾¸¶¹°ÌÀ¡¢´äºäÔèÆó (2001)
    µõ·ìÀ­¿´¼À´µ¤ËÂФ¹¤ë¼«²È¹ü¿ñ ñ³ËµåºÙ˦°Ü¿¢¤òÍѤ¤¤¿·ì´É¿·À¸ÎÅË¡¤Î´ðÁÃŪ¸¡Æ¤.
    ½Û´Ä´ï°å¡¡9:199-207
  10. ¿ÀÈ«¡¡¹¨¡¢À¾¾å¾°»Ö¡¢»°¹¥¹­Åµ¡¢ÀÆÆ£Âç¼ù¡¢°Ë¼¼Íµ²ð¡¢µÜºäÍÛ»Ò¡¢Æ£»³Áí °ìϺ¡¢·ª¸¶ÍµÉ§¡¢ÄÍ¡¡Ë§ÌÀ¡¢¾¾ËÜŵ»Ò¡¢Î©ÀзÃΤ»Ò¡¢¾¾¸¶¹°ÌÀ¡¢´äºäÔèÆó (2001)
    ¹ü¿ñºÙ˦°Ü¿¢¤Ë¤è¤ë·ì´É¿·À¸ÎÅË¡.
    Med Technol 29:583-585
  11. ¾®ºêÆÆ»Ö¡¢¾¾¸¶¹°ÌÀ¡¢Ä¹Ã«ÀîδÀµ¡¢´äºäÔè¥Ë¡¡(2001)¡¡
    ÅüÇ¢ÉÂÀ­¿Õ¾É¤Î°ä ÅÁÁǰø¡¡¥¢¥ó¥®¥ª¥Æ¥ó¥·¥Î¡¼¥²¥ó¡ÊM235T¡Ë¡¡
    ¿Õ¤ÈÆ©ÀÏ¡¡Î×»þÁý´©¹æ¡§ 77-79
  12. À¸¿å ¹¸¡¢ÁáÀî ·É¡¢»°Âð Ë­¡¢¹ñËܵÁ§¡¢À¾Àî¸÷½Å (2001)
    ÅüÇ¢ÉÂ¤ÎÆ©ÀÏ´µ¼Ô¤Î±ÉÍÜ¡¦¿©»ö´ÉÍý.
    Î×±É 99:882-885

³Ø²ñȯɽ

  1. ȪÅÄ·û¸ã¡¢ÃæÂ¼À¿»Ö¡¢ÃݲְìºÈ¡¢Åò»³ÎáÊ塢̣¼ ½ã¡¢ßÀÅÄ¿®°ì¡¢·ª¸¶ÍµÉ§¡¢ ´äºäÔèÆó¡¢¿û Ë­¡¢¿ù±ºÅ¯Ï¯ (2001)
    Quantitative ECG-gated SPECT Image at End-Diastole May More Accurately Estimate Myocardial Viability after Primary PTCA in Patients with Myocardial Infarction.
    Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ, µþÅÔ
  2. Ê¡°æÀ¯·Ä¡¢ÃæÂ¼À¿»Ö¡¢ÈªÅÄ·û¸ã¡¢ßÀÅÄ¿®°ì¡¢·ª¸¶ÍµÉ§¡¢ÃݲְìºÈ¡¢ÇÏÅÂÀµ¿Í¡¢¿ù±ºÅ¯Ï¯¡¢´äºäÔèÆó¡¡(2001)
    Early Prediction of the Final Infarct Size by Scintigraphic Estimation of Myocardial Perfusion Immediately After Successful Primary Coronary Angioplasty.
    Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ,¡¡µþÅÔ
  3. ÃæÂ¼À¿»Ö¡¢ÈªÅÄ·û¸ã¡¢ÅÏî´½á»Ò¡¢ÃݲְìºÈ¡¢ßÀÅÄ¿®°ì¡¢·ª¸¶ÍµÉ§¡¢ÇÏÅÂÀµ ¿Í¡¢¿ù±ºÅ¯Ï¯¡¢´äºäÔèÆó (2001)
    The Mechanism Related to ST-segment Reelevation After Primary Coronary Angioplasty.
    Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí ²ñ, µþÅÔ
  4. ·ª¸¶ÍµÉ§¡¢ÈªÅÄ·û¸ã¡¢ÃæÂ¼À¿»Ö¡¢ßÀÅÄ¿®°ì¡¢ÃݲְìºÈ¡¢Åò»³ÎáÊ塢̣¼ ½ã¡¢ ¿ù±ºÅ¯Ï¯¡¢´äºäÔèÆó(2001)
    Detection of Stunned Myocardium and its Relation to Functional Recovery of Left Ventricular Function After Succseeful Primary PTCA.
    Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ, µþÅÔ
  5. ÃæÂ¼À¿»Ö¡¢ÈªÅÄ·û¸ã¡¢ßÀÅÄ¿®°ì¡¢·ª¸¶ÍµÉ§¡¢ÃݲְìºÈ¡¢ÅÏî´½á»Ò¡¢ÇÏÅÂÀµ ¿Í¡¢¿ù±ºÅ¯Ï¯¡¢´äºäÔèÆó(2001)
    Quantitative Estimation of Myocardial Salvage After Primary Coronary Angioplasty in Patients With Angiographic No Reflow. Coronary Angioplasty in Patients With Angiographic No Reflow.
    ¡¡¡¡Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ,¡¡µþÅÔ
  6. ÃݲְìºÈ¡¢Ruiz¡¡Mirta¡¢Riou¡¡Laurent M¡¢´äºäÔèÆó¡¢Watson¡¡Denny D¡¢ Beller¡¡George A, Glover¡¡David K (2001)
    123I-BMIPP uptake is enhanced relative to perfusion when injected early after reflow in a canine model of reperfused, viable myocardium.
    Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ, µþÅÔ
  7. ÃݲְìºÈ¡¢Ruiz¡¡Mirta¡¢Petruzella¡¡Frank D¡¢ÃæÂ¼À¿»Ö¡¢´äºäÔèÆó¡¢Watson¡¡ Denny D¡¢Beller¡¡George A¡¢Glover¡¡David K (2001)
    99mTc-sestamibi uptake accurately predicts myocardial viability in a canine model of partial coronary reperfusion through a severe residual stenosis.
    Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ, ¡¡¡¡µþÅÔ
  8. Ê¡°æÀ¯·Ä¡¢ÃæÂ¼À¿»Ö¡¢ÈªÅÄ·û¸ã¡¢ÃݲְìºÈ¡¢ßÀÅÄ¿®°ì¡¢ËåÈø ·ò¡¢´äºäÔè Æó (2001)
    Primary PTCA¾ÉÎã¤Ë¤ª¤±¤ëNicorandil ¤Î¿´¶Ú·ìή²þÁ±¸ú²Ì Technetium-99m Tetrofosmin ¿´¶ÚSPECT¤òÍѤ¤¤¿¸¡Æ¤.¡¡
    Âè49²óÆüËÜ¿´Â¡ ɳزñ³Ø½Ñ½¸²ñ¡¢ ¹­Åç
  9. ȪÅÄ·û¸ã¡¢ÃæÂ¼À¿»Ö¡¢¿ù±ºÅ¯Ï¯¡¢ÃݲְìºÈ¡¢·ª¸¶ÍµÉ§¡¢´äºäÔèÆó (2001)
    QGS ¤Î³ÈÄ¥Ëö´üÁü¤ÏºÆÁÂÄÌ¿´¶Ú¤ÎÊɱ¿Æ°¤Î²óÉü¤ò¤è¤êÀµ³Î¤Ëͽ¬¤·¤¦¤ë.
    Âè41 ²óÆüËÜ³Ë°å³Ø²ñÁí²ñ, ¶âÂô
  10. ·ª¸¶ÍµÉ§¡¢ÃæÂ¼À¿»Ö¡¢ÈªÅÄ·û¸ã¡¢ÃݲְìºÈ¡¢ßÀÅÄ¿®°ì¡¢Ê¡°æÀ¯·Ä¡¢ÃæÂ¿°Í »Ò¡¢´äºäÔèÆó(2001)
    Primary PTCAľ¸å¤ÎStunned Myocardium¤Î¸¡½Ð-QGS ¤òÍѤ¤¤¿¸¡Æ¤-.
    Âè41²óÆüËÜ³Ë°å³Ø²ñÁí²ñ, ¶âÂô
  11. Ê¡°æÀ¯·Ä¡¢ÃæÂ¼À¿»Ö¡¢ÈªÅÄ·û¸ã¡¢ÃݲְìºÈ¡¢ßÀÅÄ¿®°ì¡¢ËåÈø ·ò¡¢´äºäÔè Æó (2001)
    Primary PTCA¾ÉÎã¤Ë¤ª¤±¤ëNicorandil ¤Î¿´¶Ú·ìή²þÁ±¸ú²Ì Technetium-99mTetrofosmin ¿´¶ÚSPECT¤òÍѤ¤¤¿¸¡Æ¤.
    Âè41²óÆüËÜ³Ë °å³Ø²ñÁí²ñ, ¶âÂô
  12. µÜºäÍÛ»Ò, ÄÔ µ×»Ò, »³Åĸ÷°ì, ÆÁ±Ê ÃÒ, À¾¾å¾°»Ö, ´äºäÔèÆó (2001)
    ·ò ¿Ç¤Çǧ¤á¤¿Brugada·¿¿´ÅſޤÎÄÉÀ×Ä´ºº.
    Âè98²óÆüËÜÆâ²Ê³Ø²ñÁí²ñ¡¢ ²£ÉÍ
  13. Miyasaka Y, Tsuji H, Yamada K, Tokunaga S, Iwasaka T and Sugiura T (2001)
    Prevalence and mortality of the Brugada type electrocardiogram in a general population.
    Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ¡¢µþÅÔ
  14. Tsuji H, Oue K, Yamada K and Iwasaka T (2001)
    A randomized study to compare 3mg with 5mg of warfarin as a starting dose for Japanese patients with atrial fibrillation.
    Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ¡¢µþÅÔ
  15. Yamamoto Y, Kamihata H, Tsuji H, Morita Y, Miyoshi H, Yamada K, Hatada K and Iwasaka T (2001)
    The DD genotype of the angiotensin I-converting enzyme is a major risk factor for diffuse in-stent restenosis.
    Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ¡¢ µþÅÔ
  16. Yamada K, Tsuji H, Tokunaga S and Iwasaka T (2001)
    Effect of beta-blockers on mortality of Japanese patients after acute myocardial infarction in the reperfusion era.
    ¡¡Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ¡¢µþÅÔ
  17. Nagahama Y, Tsuji H, Kamihata H, Morita Y, Yamamoto Y, Miyoshi H, Hatada K, Yamada K, Tsuka Y, Kawamura A and Iwasaka T (2001)
    Differences in clinical features and prevalence of coronary artery disease between Japan and USA.
    Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ¡¢µþÅÔ
  18. Tsuji H, Yamada K, Kimura Y and Iwasaka T (2001)
    Anemia affects plasma brain natriuretic peptide (BNP) level.
    Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ¡¢µþÅÔ
  19. Motohiro M, Kudou Y, Fukui M, Baden M, Sugiura T, Yuasa F and Iwasaka T(2001)
    Relation between postexercise systolic blood pressure response and myocardial ischemia assessed by technetium-99m tetrofosmin.
    Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí ²ñ¡¢µþÅÔ
  20. ¡¡Yuyama R, Yuasa F, Mimura J, Kawamura A and Iwasaka T(2001)
    Angiotensin II receptor antagonist improves endothelium mediated vasodilation in patients with chronic heart failure.
    Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ¡¢µþÅÔ
  21. Mimura J, Yuasa F, Yuyama R, Kawamura A and Iwasaka T(2001)
    The role of cardiac and peripheral sympathetic function on exercise capacity in patients with left ventricular dysfunction.
    Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ¡¢µþÅÔ
  22. Mimura J, Yuasa F, Yuyama R, Kawamura A and Iwasaka T(2001)
    Sympathetic effect of peripheral chemoreflex activation at rest and during exercise in mild heart failure.
    Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ¡¢µþÅÔ
  23. Kawamura A, Yuasa F, Yuyama R, Mimura J and Iwasaka T(2001)
    The effect of alpa-adrenergic agonist on baroreflex control of heart rate and sympathetic nerve activity in patients with left ventricular dysfunction.
    Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñ Áí²ñ¡¢µþÅÔ
  24. ¡¡Åò»³ÎáÊå¡¢ÅòÀõʸͺ¡¢Ì£Â¼ ½ã¡¢´äºê¿¿²Â¡¢²Ï¼¹¸¹°¡¢´äºäÔèÆó(2001)
    ¥·¥ó¥Ý¥¸¥¦¥à¡ÚÎ×¾²³Æ²ÊÎΰè¤Ë¤ª¤±¤ë±¿Æ°À¸Íý¥ê¥Ï¥Ó¥ê¥Æ¡¼¥·¥ç¥ó¡Û µÞÀ­¿´¶Ú¹¼ºÉ¾É²óÉü´ü¤Ë¤ª¤±¤ëû´ü±¿Æ°ÎÅË¡¤¬¼«Î§¿À·Ð¤ËÍ¿¤¨¤ë±Æ¶Á
    Âè38²óÆüËÜÎ×¾²À¸Íý³Ø²ñÁí²ñ, ½©ÅÄ
  25. ¡¡´äºê¿¿²Â¡¢ÅòÀõʸͺ¡¢Åò»³ÎáÊ塢̣¼ ½ã¡¢²Ï¼¹¸¹°¡¢´äºäÔèÆó(2001)
    ¿´ÉÔÁ´¤Ë¤ª¤±¤ë·ì´ÉÆâÈ鵡ǽ¤È¸ò´¶¿À·Ð¤ÎÁê¸ßºîÍÑ.
    Âè38²óÆüËÜÎ×¾²À¸Íý³Ø²ñÁí²ñ, ½©ÅÄ
  26. ¡¡²Ï¼¹¸¹°¡¢ÅòÀõʸͺ¡¢Åò»³ÎáÊ塢̣¼ ½ã¡¢´äºê¿¿²Â¡¢´äºäÔèÆó(2001)
    ËýÀ­¿´ÉÔÁ´¤Ë¤ª¤±¤ë¿´ÇÙ°µ¼õÍÆÂÎÈ¿¼Íµ¡Ç½¤È¿À·Ð±ÕÀ­°ø»Ò¤Î¸¡Æ¤.
    Âè38²óÆüËÜÎ×¾²À¸Íý³Ø²ñÁí²ñ, ½©ÅÄ
  27. ²Ï¼¹¸¹°¡¢ÅòÀõʸͺ¡¢Åò»³ÎáÊ塢̣¼ ½ã¡¢´äºê¿¿²Â¡¢´äºäÔèÆó(2001)
    ËýÀ­¿´ÉÔÁ´Îã¤Ë¤ª¤±¤ë¿´ÇÙ°µ¼õÍÆÂÎÈ¿¼Íµ¡Ç½¤È¿À·Ð±ÕÀ­°ø»Ò¤Î´Ø·¸.
    Âè49²óÆüËÜ¿´Â¡É³زñÁí²ñ¡¢¹­Åç
  28. ÀÆÆ£Âç¼ù¡¢ÅòÀõʸͺ¡¢¿ÀÈ«¹¨¡¢¹â»³¹¯Éס¢´äºäÔèÆó(2001)
    µÞÀ­¿´¶Ú ¹¼ºÉ¾É¤Ë¤ª¤±¤ëChest Pain Center¤ÎÍ­ÍÑÀ­.Âè49²óÆüËÜ¿´Â¡É³زñÁí²ñ¡¢ ¹­Åç
  29. ¹©Æ£½ç¹°¡¢¸µ¹­¾­Ç·¡¢ºäËÜ·ûɧ¡¢Ê¡°æÀ¯·Ä¡¢ÅòÀõʸͺ¡¢ÇÏÅÂÀµ¿Í¡¢¿ù±º ůϯ¡¢´äºäÔèÆó(2001)
    Exercise hypertension(Ex-HT)¤È´§Æ°Ì®¼À´µ(CAD)¤Î ´Ø·¸¤Ë¤Ä¤¤¤Æ.
    Âè98²óÆüËÜÆâ²Ê³Ø²ñÁí²ñ¡¢²£ÉÍ
  30. À¾¾å¾°»Ö¡¢´äºäÔèÆó¡Ê2001¡Ë
    µõ·ìÀ­¿´¼À´µ¤Ëȼ¤¦ÉÔÀ°Ì®¤ò½¤¾þ¤¹¤ë°ø»Ò ¡Ê¥Ñ ¥Í¥ë¥Ç¥£¥¹¥«¥Ã¥·¥ç¥ó¡Ë.
    Âè28²óÆüËܽ¸Ãæ¼£ÎųزñÁí²ñ¡¢Åìµþ
  31. Hamada H, Nishiue T, Nakamura S and Iwasaka T (2001)
    Relation between transmural trends of myocardial integrated backscatter and infarct expansion in-patients with acute Q wave anterior myocardial infarction.
    Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ¡¢µþÅÔ
  32. Nishiue T, Kamihata H, Matsubara H, Tsutsumi Y, Fujiyama S and Iwasaka T(2001)
    Evaluation of Therapeutic Angiogenesis Using Myocardial Contrast Echocardiography.
    Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ¡¢µþÅÔ
  33. Hamada H, Nishiue T, Nakamura S, Kamihata H and Iwasaka T(2001)
    TIMI Frame Count Immediately After Successful Primary Coronary Angioplasty as a Predictor of Functional Recovery in Patients With Acute Myocardial Infarction.
    Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ¡¢µþÅÔ
  34. Matsumoto N, Nishiue T, Kimura Y, Takayama Y, Imuro Y and Iwasaka T (2001)
    The Greater Amount of Sub-pericardial Fat is Associated With Left Ventricular Diastolic Dysfunction in Obese Subjects.
    Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ¡¢µþÅÔ
  35. »þ²¬¿¿Íý¡¢À¾¾å¾°»Ö¡¢ÃæÂ¼À¿»Ö¡¢ÈªÅÄ·û¸ã¡¢´äºäÔèÆó(2001)
    ¿´¶Ú¹¼ºÉ¤Ë¤ª ¤±¤ëPower Doppler¿´¶Ú¥³¥ó¥È¥é¥¹¥È¥¨¥³¡¼¤ÈTc-99m-tetrofosmin¿´ ÅÅ¿ÞÆ±´üÄêÎÌŪ¿´¶Ú¥·¥ó¥Á¤Ë¤è¤ë¿´¶Ú·ìή¤ÎÈæ³Ó.
    Âè49²óÆüËÜ¿´Â¡ÉÂ³Ø ²ñÁí²ñ¡¢¹­Åç
  36. ÄÔ µ×»Ò¡¢°æ¾å Ű¡¢±àÆ£ÍÛ»Ò¡¢ËÌÀî¹á¿¥¡¢ÌÚ¸¶ ͵ (2001)
    Î×¾²±Ö³Ø¤òÂêºà¤È¤·¤¿¼ÂÁ©Åª¤Ê°å³ØÅý·×½èÍý±é½¬¤Î»î¤ß¤È¤½¤Îɾ²Á.
    Ê¿À® 13ǯÅÙ¾ðÊó½èÍý¶µ°é¸¦µæ½¸²ñ¡¢Ï²λ³
  37. Miyoshi H, Kamihata H, Kawamura T, Tsuka Y, Hatada K, Yamada K, Yamamoto Y, Nagahama Y, Morita Y and Iwasaka T (2001)
    Glycemic Control and In-Stent Restenosis in Patients with Diabetes Mellitus.
    Âè65ÆüËܽ۴ĴïɳزñÁí²ñ¡¢µþÅÔ
  38. Hara H, Morita Y, Kamihata H, Hirowatari Y, Iwasaka T and Takahashi H (2001)
    Usefulness of measurement of plasma and whole blood serotonin levels in patients with ischemic heart diseases.
    Âè65ÆüËܽ۴ĴïɳزñÁí²ñ¡¢µþÅÔ
  39. Yamada K,Tsuka H,Tokunaga T, Watanabe J, Miyasaka Y and Iwasaka T (2001)
    Effect of Beta-blockers on Mortality of Japanese Patients after Acute Myocardial Infarction in the Reperfusion Era.
    Âè65ÆüËܽ۴Ĵï ɳزñÁí²ñ¡¢µþÅÔ
  40. ȪÅÄ·û¸ã¡¢ÄÍ¡¡Ë§ÌÀ¡¢»³ËÜů»Ë¡¢²Ï¼¹¸¹°¡¢´äºäÔèÆó (2001)
    small vessel ¤ËÂФ¹¤ëstentαÃÖ¤ÎÍ­ÍÑÀ­.
    Âè1²ó ÆüËÜ¿´·ì´É¥«¥Æ¡¼¥Æ¥ë¼£Îųزñ ¡¢ ¾®ÁÒ
  41. »°¹¥¹­Åµ¡¢¿ÀÈ«¡¡¹¨¡¢¿ÝëÊÝÉס¢±ÊßÀ¡¡Íס¢»³Åĸ÷°ì¡¢ÈªÅÄ·û¸ã¡¢ÄÍ¡¡Ë§¡¡ ¡¡¡¡ÌÀ¡¢»³ËÜů»Ë¡¢²Ï¼¹¸¹°¡¢´äºäÔèÆó (2001)
    ÅüǢɴµ¼Ô¤Ë¤ª¤¤¤Æ¥¤¥ó ¡¡¡¡¥¿¡¼¥Ù¥ó¥·¥ç¥ó»þ¤Î·ìÅü¥³¥ó¥È¥í¡¼¥ë¤Ï¥¹¥Æ¥ó¥ÈºÆ¶¹ºõ¤ò¸º¾¯¤µ¤»¤ë¤«¡©
    ¡¡ ¡¡¡¡Âè1²ó ÆüËÜ¿´·ì´É¥«¥Æ¡¼¥Æ¥ë¼£Îųزñ¡¢ ¾®ÁÒ
  42. »°¹¥¹­Åµ¡¢¿ÀÈ«¡¡¹¨¡¢¿ÝëÊÝÉס¢±ÊßÀ¡¡Íס¢»³Åĸ÷°ì¡¢ÈªÅÄ·û¸ã¡¢ÄÍ¡¡Ë§¡¡ ¡¡¡¡ÌÀ¡¢»³ËÜů»Ë¡¢²Ï¼¹¸¹°¡¢´äºäÔèÆó (2001)
    ÅüǢɴµ¼Ô¤Ë¤ª¤¤¤Æ¥¤¥ó¥¿¡¼¡¡ ¡¡¡¡¥Ù¥ó¥·¥ç¥ó»þ¤Î·ìÅü¥³¥ó¥È¥í¡¼¥ë¤Ï¥¹¥Æ¥ó¥ÈºÆ¶¹ºõ¤ò¸º¾¯¤µ¤»¤ë¤«¡©
    ¡¡¡¡Âè49²óÆüËÜ¿´Â¡É³زñ³Ø½Ñ½¸²ñ¡¢¹­Åç
  43. Tsuka Y, Nagahama Y, Kamihata H, Morita Y, Yamamoto Y, Miyoshi H, Hatada K, Yamada K, Kawamura A and Iwasaka T¡¡(2001)
    Cutting Balloon Angioplasty Before Stenting has a Benefit for In-stent Restenosis.
    Âè65²óÆüËܽ۴ĴïɳزñÁí²ñ µþÅÔ
  44. ÄÍ¡¡Ë§ÌÀ¡¢¿ù±ºÅ¯Ï¯¡¢ÈªÅÄ·û¸ã¡¢±ÊßÀ¡¡Íס¢´äºäÔèÆó (2001)
    µÞÀ­²¼Êɹ¼ ¡¡¡¡ºÉ ¤Ë¤ª¤±¤ëÁ°¶»ÉôͶƳ¡ÊV1¡¢V2¡ËST¾å¾º¤ÎÎ×¾²Åª°ÕµÁ¡¥
    ¡¡ Âè28²óÆüËܽ¸Ãæ¼£ÎŰ峨²ñ ¡¢Åìµþ
  45. ÄÍ¡¡Ë§ÌÀ¡¡¿¹ÅÄ¡¡´²¡¢¿ÀÈ«¡¡¹¨¡¢¿ÝëÊÝÉס¢±ÊßÀ¡¡Íס¢»°¹¥¹­Åµ¡¢»³Åĸ÷¡¡ °ì¡¢ ȪÅÄ·û¸ã¡¢»³ËÜů»Ë¡¢²Ï¼¹¸¹°¡¢µþ°æ»Ö¿¥¡¢´Ó°æÌ¤Æà»Ò¡¢¸¶¡¡¹î»Ò¡¢¡¡ ¹â¶¶ÇìÉס¢´äºäÔèÆó (2001)
    ¥¹¥Æ¥ó¥ÈÆâºÆ¶¹ºõ¤È±ê¾É¤È¤Î´ØÏ¢¡¥
    Âè1²óÆüËÜ¿´·ì´É¥«¥Æ¡¼¥Æ¥ë¼£Îųزñ¡¢ ¾®ÁÒ
  46. ÄÍ¡¡Ë§ÌÀ¡¢±ÊßÀ¡¡Íס¢¿ÀÈ«¡¡¹¨¡¢¿ÝëÊÝÉס¢»°¹¥¹­Åµ¡¢»³Åĸ÷°ì¡¢ÈªÅÄ·û ¸ã¡¢»³ËÜů»Ë¡¢²Ï¼¹¸¹°¡¢µþ°æ»Ö¿¥¡¢´Ó°æÌ¤Æà»Ò¡¢¸¶¡¡¹î»Ò¡¢¹â¶¶ÇìÉס¢ ´äºäÔèÆó (2001)
    ´§Ú»½Ì¤È±ê¾É¤È¤Î´ØÏ¢¡¥
    Âè1²ó¡¡ÆüËÜ¿´·ì´É¥«¥Æ¡¼¥Æ ¥ë¼£Îųزñ¡¢ ¾®ÁÒ
  47. ÄÍ¡¡Ë§ÌÀ¡¢±ÊßÀ¡¡Íס¢¿ÀÈ«¡¡¹¨¡¢¿ÝëÊÝÉס¢»°¹¥¹­Åµ¡¢»³Åĸ÷°ì¡¢ÈªÅÄ·û ¸ã¡¢»³ËÜů»Ë¡¢²Ï¼¹¸¹°¡¢µþ°æ»Ö¿¥¡¢´Ó°æÌ¤Æà»Ò¡¢´äºäÔèÆó (2001)
    Cutting Balloon¤Ë¤è¤ëStentÁ°³ÈÄ¥¤ÎÍ­¸úÀ­¡¥
    Âè1²ó¡¡ÆüËÜ¿´·ì´É¥«¥Æ¡¼¥Æ¥ë ¼£Îųزñ¡¢ ¾®ÁÒ
  48. Kamihata H, Matsubara H, Nishiue T, Tsutusmi Y, Fujiyama S, Masaki H and Iwasaka T(2001)
    Therapeutic angiogenesis of ischemic myocardium using autologous bone marrow cell implantation that side-supplies of angioblasts, angiogenic ligands and cytokines.
    Âè65²ó ÆüËܽ۴ĴïɳزñÁí²ñ¡¢µþÅÔ
  49. Kamihata H, Iwasaka T, Fujiyama S, Tsutusmi Y, Nishiue T and Matsubara H (2001)
    Implantation of Autologous Bone Marrow Cells into Ischemic Myocardium Enhances Collateral Perfusion and Regional Function via Sude-supply of Angioblasts and Angiogenic Ligands (VEGF ,bFGF,Angiopoietin-1).
    Âè65²ó ÆüËܽ۴ĴïɳزñÁí²ñ¡¢µþÅÔ
  50. Æâ»³ÍÕ»Ò¡¢¾¾¸¶¹°ÌÀ¡¢¿¹¡¡ÂÙÀ¶¡¢¼ÆºêÂٱ䡢ǽÀªÆØ»Ò¡¢ÇßÅŬµ×¡¢±ÊÅÄ ÅÐ »Ö»Ò¡¢´äºäÔèÆó¡Ê2001¡Ë
    TGF-¦Â¤Ë¤è¤ëFibronectin°äÅÁ»Òȯ¸½¤Ï¾åÈéÀ®Ä¹ °ø»Ò¼õÍÆÂΤζ¦Ìò³èÀ­²½¤ò²ð¤·¤ÆÄ´Àᤵ¤ì¤ë.
    Âè44²óÆüËܿա³Ø²ñ³Ø½Ñ Áí²ñ¡¢Åìµþ
  51. ǽÀªÆØ»Ò¡¢¿¹¡¡ÂÙÀ¶¡¢¾¾¸¶¹°ÌÀ¡¢Æâ»³ÍÕ»Ò¡¢¾®ºêÆÆ»Ö¡¢ÀµÌÚ¹ÀºÈ¡¢¼Æºê Âٱ䡢ÇßÅŬµ×¡¢±ÊÅÄÅлֻҡ¢´äºäÔèÆó¡Ê2001¡Ë
    ¥¢¥ó¥¸¥ª¥Æ¥ó¥·¥óII¤Ï HB¡ÝEGFʬÈç¤ò²ð¤·¤Æ¾åÈéÀ®Ä¹°ø»Ò¼õÍÆÂΤò¶¦Ìò ³èÀ­²½¤µ¤»glucose transporter¡ÊGlut1¡Ë°äÅÁ»Òȯ¸½¤òж¿Ê¤¹¤ë.
    Âè44²óÆüËܿա³Ø²ñ³Ø½ÑÁí²ñ¡¢ Åìµþ
  52. ¿¹¡¡ÂÙÀ¶¡¢Æâ»³ÍÕ»Ò¡¢Ç½ÀªÆØ»Ò¡¢´ßËÜŵ»Ò¡¢ÀµÌÚ¹ÀºÈ¡¢±ÊÅÄÅлֻҡ¢ÇßÅÄ ¹¬µ×¡¢¾¾¸¶¹°ÌÀ¡¢´äºäÔèÆó¡Ê2001¡Ë
    ¥Ñ¥ë¥Ü¥¦¥£¥ë¥¹´¶À÷¾É¤Ë¤è¤ëµÞÀ­»å µåÂοձê¤Î°ìÎã.
    Âè31²óÆüËܿա³Ø²ñÀ¾Éô³Ø½ÑÂç²ñ¡¢¶âÂô
  53. ¿¹¡¡ÂÙÀ¶¡Ê2001¡Ë
    ¿Õ¼À´µ¤Î±ÉÍÜ¡¦¿©»ö´ÉÍý¡Ê´ðÄ´¹Ö±é¡Ë.
    Âè48²óÆüËܱÉÍܲþÁ±³Ø²ñ³Ø½ÑÁí²ñ¡¢Âçºå
  54. ¾®ºêÆÆ»Ö¡¢ÌÚ¼¡¡¾÷¡¢¾®¾¾¡¡¹á¡¢»³ËÜů»Ë¡¢¾åÅÄ²ÃÆà»Ò¡¢µ×ÊÝÅÄâÃͳÈþ¡¢¡¡ ¡¡¡¡´äºäÔè¥Ë¡Ê2001¡Ë
    ¡¡ÅüǢɿÇÎŤˤª¤±¤ëÃϰ豿ư»ØÆ³»Î¤È¤Î¥Á¡¼¥à¥×¥ì¥¤ ¡¡¡¡? µþºå¥á¥Ç¥£¥«¥ë¥Õ¥£¥Ã¥È¥Í¥¹¥Í¥Ã¥È¥ï¡¼¥¯¤ÎÀßΩ-
    ¡¡Âè38²óÆüËÜÅüǢɠ³Ø²ñ¶áµ¦ÃÏÊý²ñ¥·¥ó¥Ý¥¸¥¦¥à¡¢Âçºå
  55. ¾®ºêÆÆ»Ö¡¢ÌÚ¼¡¡¾÷¡¢´äºäÔè¥Ë(2001)
    ÀìÌç°åÎŵ¡´Ø¤ÈÊ£¿ô¤Î±¿Æ°»ÜÀß ¡¡¡¡¤È¤ÎÏ¢·È ?À¸³è½¬´·É´µ¼Ô¤Ø¤Î±¿Æ°ÎÅË¡»Ù±ç¥·¥¹¥Æ¥à¤Î¹½ÃÛ-
    ¡¡¡¡Âè15²óÎ×¾²±¿Æ°ÎÅË¡¸¦µæ²ñ¥·¥ó¥Ý¥¸¥¦¥à¡¢Âçºå
  56. ĹëÀîδÀµ¡¢¾®ºêÆÆ»Ö¡¢¾¾¸¶¹°ÌÀ¡¢¿¹ ÂÙÀ¶¡¢ÀµÌÚ¹ÀºÈ¡¢ÌÚ¼¡¡¾÷¡¢²­³À ¡¡¡¡¸÷ɧ¡¢À¸¿å ¹¸¡¢À¾Àî¸÷½Å¡¢´äºäÔè¥Ë¡¡(2001)
    S100ÃÁÇò¤Îȯ¸½Ä´Àá°ø»Ò¡¡ ¡¡¡¡¤Ë´Ø¤¹¤ë¸¡Æ¤.¡¡
    Âè44²óÆüËÜÅüǢɳزñÁí²ñ¡¢µþÅÔ
  57. Maeda A, Toyoda N, Imai Y, Nishikawa M and Iwasaka T (2001)
    Expression and regulation of type 2 iodothyronine deiodinase in human artery smooth muscle cells.
    Âè65²óÆüËܽ۴ĴïɳزñÁí²ñ¡¢µþÅÔ
  58. Ë­ÅÄŶ½¡¢Á°ÅÄ¾Ï²í¡¢º£°æÍµ»Ò¡¢À¾Àî¸÷½Å¡¢´äºäÔèÆó (2001)
    ¥Ò¥È·ì´ÉÊ¿ ³ê¶ÚºÙ˦¤Ëȯ¸½¤¹¤ë¹Ã¾õÁ£¥Û¥ë¥â¥óÂå¼Õ¹ÚÁǤÎȯ¸½Ä´Àᵡ½ø.
    Âè98²óÆü ËÜÆâ²Ê³Ø²ñÁí²ñ¡¢²£ÉÍ
  59. Okigaki M, Matsubara H and Iwasaka T (2001)
    Multiple Functional Role of PYK2 in Macrophage Migration revealed by PYK2 knock-out mice.
    Âè65²ó ÆüËܽ۴Ĵï ɳزñÁí²ñ¡¢µþÅÔ
  60. Okigaki M, Matsubara H and Iwasaka T (2001)
    Multiple Functional Role of PYK2 in Cytokine Induction from Macrophage revealed by PYK2 knock out mice.
    Âè65²ó ÆüËܽ۴ĴïɳزñÁí²ñ¡¢µþÅÔ
  61. Matsubara H(2001)
    First Report of Clinical Trial of Autologous Implantation of Bone Marrow Cells to Patients with Arteriosclerosis Obliterans-Molecular Mechanism for Marrow Cells-Induced Angiogenesis.
    Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñ Áí²ñ¡¢µþÅÔ
  62. Matsubara H, Masaki H, Tateishi E, Iwsaka T (2001)
    First Report of Clinical Trial of Autologous Implantation of Bone Marrow Cells of Patients with Arterioscle rosis Obliterans-Molecular Mechanism for Marrow Cells-Induced Angiogenesis.
    ¡¡ Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ¡¢µþÅÔ
  63. Uchiyama Y, Matsubara H, Mori Y, Kosaki A, Tsutsumi Y, Shibasaki Y, Fujiyama S, Nose A, Iba o, Hasagawa T, Tateishi E and Iwasaka T (2001)
    Comparative study of ACE Inhibitor and angiotensin2 type1 receptor antagpnist on regression of caro tid-artery IMT In hypertensives.
    ¡¡Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ¡¢µþÅÔ
  64. Matsubara H, Murasawa S, Mori Y, Shibasaki Y, Masaki H, Maruyama K, TsutsumiY, Fujiyama S, Iba O, Tateishi E and Iwasaka T (2001)
    Evidence That Intrinsic Kinase Domain of EGF Receptor Is not Involved In Angiotensin 2 mediated Transactiv ation of EGF receptor.
    Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ¡¢µþÅÔ
  65. Tsutsumi Y, Matsubara H, Mori Y, Murasawa S, Maruyama K, Shibasaki Y, Uchiyama Y, Fujiyama S, Nose A and Iwasaka T (2001)
    Angiotensin type2(AT2) ¡¡ ¡¡ receptor Inhibits AT1-mediated Intracellular alkalosis to enhance kinin ssproduction In vasucular smooth muscle cell from vascular-targeted AT2-transgenic mice.¡¡
    Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ¡¢µþÅÔ
  66. Tateishi E, Masaki H, Matsubara H, Mori Y, Shibasaki Y, Tsutsumi Y, Fujiyama S, Iba O and Iwakasa T (2001)
    Clinically Feasible Theraputic Angiogenesis using Autol ogous Implantation of Bone Marrow-derived Mononuclear Cells to Ischemic limbs.¡¡
    Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ¡¢µþÅÔ
  67. Shibasaki Y, Matsubara H, Mori Y, Masaki H, Kosaki A, Tsutsumi Y, Uchiyama Y, Fujiyama S, Nose A, Iba O, Tateishi E and Iwasaka T (2001)
    Angiotensin 2 Receptor Inhibits EGF Receptor Transactivation by Increasing Association of SHP-1 Tyro sine Phosphatase to Inactivate Mitogen-activating Protein Family Kinases.¡¡
    Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ¡¢µþÅÔ
  68. Murasawa S, Matsubara H, Mori Y, Masaki H, Tsutsumi Y, Shibasaki Y, Fujiyama S, Iba O, Tateishi E and Iwasaka T (2001)
    Angiotensin II Initiates Tyrosine Kinase Py k2-Dependent Signalings Leading to Activation to Rac1-Mediated c-Jun NH2-Ter minal Kinase.
    ¡¡Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ¡¢µþÅÔ
  69. Maruyama K, Matsubara H, Mori Y, Shibasaki Y, Masaki H, Tsutsumi Y, Fujiyama S, Iba O, Tateishi E and Iwasaka T (2001)
    Angiotensin AT1 and AT2 Receptors Differen tially Regulate the Expression of Tissue Factor In Cardiac microvascular End othelial Cells.¡¡
    Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ¡¢µþÅÔ
  70. ¼ÆºêÂٱ䡢ÀµÌÚ¹ÀºÈ¡¢À¾¾å¾°»Ö¡¢¾¾¸¶¹°ÌÀ¡¢¹â¶¶ÇìÉס¢´äºäÔèÆó(2001)
    ¥¢¥ó¥¸¥ª¥Æ¥ó¥·¥óII1·¿¼õÍÆÂÎÙɹ³Ìô¤ÎÆ©ÀÏ´µ¼Ô¤Ë¤ª¤±¤ë¿´¶ÚÈîÂ硦Á¡°Ý ²½ÍÞÀ©¸ú²Ì¤Ë¤Ä¤¤¤Æ¸¡Æ¤-ACEÁ˳²ÌôµÚ¤ÓCaÙɹ³Ìô¤È¤ÎÈæ³Ó¸¡Æ¤-
    Âè24²óÆüËܹâ·ì°µ³Ø²ñÁí²ñ¡¢Âçºå
  71. Åä¡¡µÁÌÀ¡¢¾¾¸¶¹°ÌÀ¡¢¿¹¡¡ÂÙÀ¶¡¢ÀµÌÚ¹ÀºÈ¡¢Æ£»³Áí°ìϺ¡¢°æÄí¡¡Íý¡¢¼Æºê Âٱ䡢´Éë¡¡·ò¡¢ËÙÆâÀµ»Ì¡¢Ìîß·Îɵס¢¹â¶¶ÇìÉס¢´äºäÔèÆó(2001)
    ¡¡ ¡¡ ¥¢¥ó¥¸¥ª¥Æ¥ó¥·¥óII¤È·ì´ÉºÆÀ¸¥à°äÅÁ»ÒÁàºîưʪ¤òÍѤ¤¤ÆÌÀ¤é¤«¤Ë¤Ê¤Ã¤¿ ¼õÍÆÂÎ¥µ¥Ö¥¿¥¤¥×°Í¸À­¤Îµõ·ìÉô·ì´É¿·À¸ºîÍÑ.¡¡
    Â裲£´²óÆüËܹâ·ì°µ³Ø²ñ Áí²ñ¡¢Âçºå
  72. ¡¡

  73. ½©ÅÄͺ»°¡¢ÌÚ¼¡¡¾÷¡¢¾®¾¾¡¡¹á¡¢´äºäÔèÆó(2001)
    Enhanced ventilatory response during exercise might play important role in sleep apnea of patients with heart failure.
    Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ¡¢µþÅÔ
  74. ÌÚ¼¡¡¾÷¡¢»³ËÜů»Ë¡¢¾®¾¾¡¡¹á¡¢µï¸¶ÅÄÁ±»Ê¡¢´äºäÔèÆó¡Ê2001¡Ë
    ·ì¾®ÈÄͳ¡¡ ¡¡ Íè¥Þ¥¤¥¯¥í¥Ñ¡¼¥Æ¥£¥¯¥ë¡¢·ì¾®ÈijèÀ­Êª¼Á¤Ë¤è¤ë¹â·ì°µ±¿Æ°¸ú²Ì ¤Î¸¡Æ¤.
    ¡¡ Âè49²óÆüËÜ¿´Â¡É³زñ¡¢¹­Åç
  75. ¾®¾¾¡¡¹á¡¢ÌÚ¼¡¡¾÷¡¢»³ËÜů»Ë¡¢Ä¹Ã«Àî¡¡¸¼¡¢¾¾ËÜŵ»Ò¡¢´äºäÔèÆó(2001)
    ¹â·ì°µ´µ¼Ô¤ÎÍ­»ÀÁDZ¿Æ°¤Ë¤ª¤±¤ë»ý³À­CaÙɹ³ºÞ¤Î¼«Î§¿À·ÐÈ¿±þ ¡¡ ¤ËµÚ¤Ü¤¹±Æ¶Á.
    Âè49²óÆüËÜ¿´Â¡É³زñ¡¢¹­Åç
  76. »³ËÜů»Ë¡¢ÌÚ¼¡¡¾÷¡¢¾®¾¾¡¡¹á¡¢µï¸¶ÅÄÁ±»Ê¡¢´äºäÔèÆó(2001)
    ¶áÀÖ³°Àþʬ ¸÷Ë¡¤Ë¤è¤ë±¿Æ°»þËö¾¿»ÀÁÇÆ°ÂÖ¤Îɾ²Á.
    Âè49²óÆüËÜ¿´Â¡É³زñ¡¢¹­Åç
  77. ÂçË̺»Í³Íø¡¢±º¸ýŵ»Ò¡¢ÍêÅÄÍ¥»Ò¡¢Ê¿¸¶¥ß¥«¡¢±ÊÅÄ¿¿Í³Èþ¡¢¿ùËÜ·É»Ò (2001)
    ¿´¶Ú¹¼ºÉÆþ±¡»þ¶µ°é¸ú²Ì¤Î±ó³ÖÀ®ÀÓ.
    Âè49²óÆüËÜ¿´Â¡É³زñ¡¢ ¹­Åç
  78. ¾®¾¾¡¡¹á¡¢ÌÚ¼¡¡¾÷¡¢»³ËÜů»Ë¡¢Ä¹Ã«À¡¢¾¾ËÜŵ»Ò¡¢´äºäÔèÆó(2001)
    ¹â·ì°µ´µ¼Ô¤Î»ý³Ūͭ»ÀÁDZ¿Æ°»þ¤Î·ì°µ¡¢¿´Çï¿ô¤Ë¤ª¤è¤Ü¤¹¼«Î§¿À·Ð µ¡Ç½.
    Âè40²óÆüËܹâ·ì°µ³Ø²ñÁí²ñ¡¢Âçºå
  79. »³ËÜů»Ë¡¢ÌÚ¼¡¡¾÷¡¢¾®¾¾¡¡¹á¡¢µï¸¶ÅÄÁ±»Ê¡¢´äºäÔèÆó(2001)
    ̵»ÀÁDZ¿Æ°ïçÃͤȻÀÁǸúΨ¤È¤Î´Ø·¸.
    Âè56²óÆüËÜÂÎÎÏ°å³Ø²ñ¡¢ÀçÂæ
  80. ¾åÅÄ²ÃÆà»Ò¡¢ÌÚ¼¡¡¾÷¡¢¾®¾¾¡¡¹á¡¢µï¸¶ÅÄÁ±»Ê¡¢´äºäÔèÆó(2001)
    ¥¢¥¯¥Æ¥£¥Ö¥È¥ì¡¼¥µ¡¼¤Ë¤è¤ë±¿Æ°ÎÅË¡¸ú²Ì¤Î¸¡Æ¤.
    Âè56²óÆüËÜÂÎ ÎÏ°å³Ø²ñ¡¢ÀçÂæ
  81. µ×ÊÝÅÄ¿¿Í³Èþ¡¢ÌÚ¼¡¡¾÷¡¢¾®¾¾¡¡¹á¡¢µï¸¶ÅÄÁ±»Ê¡¢´äºäÔèÆó(2001)
    ¥¹¥È¥ì¥ó¥°¥¹¥¨¥ë¥´¤Ë¤è¤ë²¼»è¶ÚÎϤε¡Ç½ÅªÉ¾²Á.
    Âè56²óÆüËÜÂÎ ÎÏ°å³Ø²ñ¡¢ÀçÂæ
  82. ¾®¾¾¡¡¹á¡¢ÌÚ¼¡¡¾÷¡¢»³ËÜů»Ë¡¢Ä¹Ã«Àî¡¡¸¼¡¢¾¾ËÜŵ»Ò¡¢´äºäÔèÆó ¡¡¡¡(2001)
    ¿´Â¡¥ê¥Ï¥Ó¥ê¥Æ¡¼¥·¥ç¥ó¤ËµÚ¤Ü¤¹¦Â£³¥¢¥É¥ì¥Ê¥ê¥ó¼õÍÆÂΰä ÅÁ»Ò¿·¿¤Î¸¡Æ¤.
    Âè7²óÆüËÜ¿´Â¡¥ê¥Ï¥Ó¥ê¥Æ¡¼¥·¥ç¥ó³Ø²ñ¡¢µ×Î±ÊÆ
  83. ÌÚ¼¡¡¾÷¡¢¾®¾¾¡¡¹á¡¢»³ËÜů»Ë¡¢µï¸¶ÅÄÁ±»Ê¡¢´äºäÔèÆó(2001)
    ·ì¾®ÈÄͳÍè¥Þ¥¤¥¯¥í¥Ñ¡¼¥Æ¥£¥¯¥ë¡¢·ì¾®ÈijèÀ­Êª¼Á¤Ë¤ª¤è¤Ü¤¹¿´Â¡ ¥ê¥Ï¥Ó¥ê¥Æ¡¼¥·¥ç¥ó¸ú²Ì.
    Âè7²óÆüËÜ¿´Â¡¥ê¥Ï¥Ó¥ê¥Æ¡¼¥·¥ç¥ó³Ø²ñ¡¢ µ×Î±ÊÆ
  84. Æ£ËÜÈ˻ҡ¢±ÊÅÄ¿¿Í³Èþ¡¢±º¸ýŵ»Ò¡¢»ù¶Ì·Ë»Ò¡¢¾åÅÄ²ÃÆà»Ò¡¢µ×ÊÝÅÄâÃͳÈþ¡¢ ¿ùËÜ¡¡·É»Ò(2001)
    ¿´Â¡¥ê¥Ï¥Ó¥ê¥Æ¡¼¥·¥ç¥ó·Ñ³Îã¤Ë¤ª¤±¤ë·Ñ³·¿¡¦¸Ä¿Í »ØÆ³ÍÑÀ¸³è½¬´·¥Á¥§¥Ã¥¯¥·¥¹¥Æ¥à¤Î³«È¯.
    Âè7²óÆüËÜ¿´Â¡¥ê¥Ï¥Ó¥ê¥Æ¡¼¥· ¥ç¥ó³Ø²ñ¡¢µ×Î±ÊÆ
  85. ÇϾìÅ·¿®¡¢ÌÚ¼¡¡¾÷¡¢¾®¾¾¡¡¹á¡¢»³ËÜů»Ë¡¢µï¸¶ÅÄÁ±»Ê¡¢´äºäÔèÆó(2001)
    ÈîËþ¼£ÎŤˤª¤±¤ë¿´Íý³ØÅª²ðÆþ¤Ë¤Ä¤¤¤Æ¡¼¿´ÍýŪɾ²Á¤Ë´ð¤Å¤¯¿´Íý¥«¥¦¥ó ¥»¥ê¥ó¥°¡¼.
    Âè10²óÆüËÜ¿´ÎÅÆâ²Ê³Ø²ñ¡¢ÀçÂæ
  86. µ×ÊÝμ»Ò¡¢ÌÚ¼¡¡¾÷¡¢¾®¾¾¡¡¹á¡¢»³ËÜů»Ë¡¢µï¸¶ÅÄÁ±»Ê¡¢´äºäÔèÆó(2001)
    ÈîËþ¶µ¼¼¤Î¿©¹ÔưÊѲ½¤ÎÂÎÁÈÀ®¡¢·ìÀ¶»é¼Á¤ËµÚ¤Ü¤¹±Æ¶Á.
    Âè39²óÆüËܱÉÍܲþÁ±³Ø²ñ¡¢Âçºå
  87. Í­Àîâûҡ¢ÌÚ¼¡¡¾÷¡¢¾®¾¾¡¡¹á¡¢»³ËÜů»Ë¡¢µï¸¶ÅÄÁ±»Ê¡¢´äºäÔèÆó (2001)
    ¼«¸Ê¿½¹ð¥¤¥á¡¼¥¸Ë¡¤Ë¤è¤ë±ÉÍÜÁÇ¡¢¿©ÉÊÊ̱ÉÍÜɾ²Á¤ÎÂÅÅöÀ­¤Ë ¤Ä¤¤¤Æ.
    Âè39²óÆüËܱÉÍܲþÁ±³Ø²ñ¡¢Âçºå
  88. ÅÄÅ躴Ï»ҡ¢ÌÚ¼¡¡¾÷¡¢¾®¾¾¡¡¹á¡¢»³ËÜů»Ë¡¢µï¸¶ÅÄÁ±»Ê¡¢´äºäÔèÆó (2001)
    ÈîËþ¿©¹Ôư¤È¸ºÎ̸ú²Ì¤Î¸¡Æ¤.
    Âè39²óÆüËܱÉÍܲþÁ±³Ø²ñ¡¢Âçºå
  89. ÇϾìÅ·¿®¡¢ÌÚ¼¡¡¾÷¡¢¾®¾¾¡¡¹á¡¢»³ËÜů»Ë¡¢µï¸¶ÅÄÁ±»Ê¡¢´äºäÔèÆó (2001)
    ÈîËþ±¿Æ°ÎÅË¡»Ü¹ÔÎã¤Ë¤ª¤±¤ë¿´ÍýŪɾ²Á¡¿¥«¥¦¥ó¥»¥ê¥ó¥°¤ÎÍ­ÍÑ À­¡Ý̵ºî°Ù³äÉդˤè¤ë¸¡Æ¤¡Ý.
    Âè22²óÆüËÜÈîËþ³Ø²ñ¡¢·²ÇÏ
  90. ÅÄÅ躴Ï»ҡ¢ÌÚ¼¡¡¾÷¡¢¾®¾¾¡¡¹á¡¢»³ËÜů»Ë¡¢µï¸¶ÅÄÁ±»Ê¡¢´äºäÔèÆó (2001)
    ¿©»ö¡¦±¿Æ°ÎÅË¡»Ü¹Ô»þ¤Î¶É½êÂλéËÃʬÉۤηлþŪÊѲ½ ¡Ý¶áÀÖ³°Ê¬¸÷Ë¡¤Ë¤è¤ëɾ²Á¡Ý.
    Âè22²óÆüËÜÈîËþ³Ø²ñ¡¢·²ÇÏ
  91. ÌÚ¼¡¡¾÷¡¢¾®¾¾¡¡¹á¡¢»³ËÜů»Ë¡¢µï¸¶ÅÄÁ±»Ê¡¢´äºäÔèÆó(2001)
    ADR¤Ë¤è¤ë¹â·ì°µ±¿Æ°ÎÅË¡¤Î¹ß°µ¸ú²Ì¤Î¸¡Æ¤.
    Âè12²óÎ×¾²¥¹¥Ý¡¼¥Ä°å³Ø²ñ¡¢Åìµþ
  92. »³ËÜů»Ë¡¢ÌÚ¼¡¡¾÷¡¢¾®¾¾¡¡¹á¡¢µï¸¶ÅÄÁ±»Ê¡¢´äºäÔèÆó(2001)
    ¹âÎð¼Ô±¿Æ°ÎÅË¡¤Ë¤ª¤±¤ë¥¹¥Æ¥Ã¥×¥¨¥¯¥µ¥µ¥¤¥º¤Î¸¡Æ¤.
    Âè36²óÆüËÜÎ×¾²À¸Íý³Ø²ñÁí²ñ¡¢½©ÅÄ
  93. »³ËÜů»Ë¡¢ÌÚ¼¡¡¾÷¡¢¾®¾¾¡¡¹á¡¢µï¸¶ÅÄÁ±»Ê¡¢´äºäÔèÆó(2001)
    ¶áÀÖ³°Àþʬ¸÷Ë¡¤Ë¤è¤ë»ÀÁǸúΨ.
    Âè29²óÆüËÜÌ®´É³Ø²ñÁí²ñ¡¢Âçºå
  94. Nakamura S, Hatada, K, Kurihara H, Takehana K, Suga Y and Iwasaka. T (2001)
    Quantitative-gated SPECT Imaging in the Detection of Stunned Myocardium and its Relation to Functional Recovery of Left Ventricular Function After Successful Primary Coronary Angioplasty.
    48th Annual Meeting of Seminar of Nuclear Medicine, Tronto, Canada.
  95. Nakamura S, Hatada K, Kurihara H, Takehana K, Suga Y and Iwasaka.T (2001)
    Detection of Stunned Myocardium Determinating Recovery of Wall Motion in the Reperfused Area by Quantitative-gated SPECT at Early After Reperfusion.
    48th Annual Meeting of Seminar of Nuclear Medicine, Tronto, Canada.
  96. Hatada K, Nakamura S, Sugiura T, Kamihata H, Takehana K, Suga Y, Yuyama R, Mimura J, Hamada S, Kurihara H and Iwasaka T (2001)
    Quantitative-ECG gated Myocardial perfusion Imaging at End-diastole Accurately Estimates Myocardial Viability After Primary PTCA in Patients With Myocardial Infarction.
    48th Annual Meeting of Seminar of Nuclear Medicine, Tronto, Canada.
  97. Fukui M, Baden M, Kurihara H, Iwasaka T, Nakamura S and Sugiura T (2001)
    Early Prediction of Final Infarct Size by Scintigraphic Estimation of Myocardial Perfusion Immediately After Successful Primary Coronary Angioplasty.
    XXII th congress of the European Society of Cardiology, Stockholm Sweden.
  98. Mori Y, Uchiyama-Tanaka Y, Kosaki A, Matsubara H and Iwasaka T (2001)
    Involvement of EGF/FRK transactivation pathway in TGF-¦Â-induced MCP-1 expression in renal tubular epithelial cells.
    The 36th Annual meeting of American society of nephrology, San Francisco.
  99. Uchiyama-Tanaka Y, Matsubara H, Masaki H, Shibasaki Y and Iwasaka T (2001)
    TGF-¦Â signaling in glomerular mesangial cells: Involvement of HB-EGF and EGF receptor transactivation in TGF-¦Â-induced fibronectin expression.
    The 36th Annual meeting of American society of nephrology, San Francisco.
  100. Yuyama R, Yuasa F, Mimura J, Kawamura A, Sugiura T and Iwasaka T(2001)
    Endothelial-mediated vasoconstriction is not involved in the sympathetic neural outflow in patients with heart failure.
    XXIII congress of the european society of cardiology, Sweden.
  101. Kawamura A, Yuyama R, Yuasa F, Mimura J, Sugiura T and Iwasaka T(2001)
    The effect of clonidine on baroreflex control of heart rate and sympathetic nerve activity in patients with heart failure.
    XXIII congress of the european society of cardiology, Sweden.
  102. Nishiue T, Kamihata H, Matsubara H, Fujiyama S, Tsutsumi Y, Tokioka M and Iwasaka T(2001)
    Myocardial Contrast Echocardiography is a Feasible Method to Evaluate Neovascularization by Autologous Implantation of Bone Marrow Cells.
    50th American college of cardiology ,Orland.
  103. Kamihata H, Matsubara H,Nishiue T, Fujiyama S, Iba O, Tateishi E and Iwasaka T (2001)
    Evaluation of Potential Side-Effects by Implantation of Bone Marrow-Derived Mononuclear Cells intoPorcine Ischemic Myocardium.
    American Heart Association Scientific Session , Anahaim¡¡
  104. Okigaki M, Matsubara H and Iwasaka T (2001
    ) Critical Role of PYK2 in Macrophage Function which are involved in Atherogenesis.
    American Heart Association Scientific Session , Anahaim
  105. Tateishi E, Matsubara H, Murohara T, Shintani S, Imaizumi T and Iwasaka T(2001)
    Efficacy and safety of therapeutic angiogenesis using autologous bone marrow cell implantation for critical limb ischemia.
    American Heart Association Scientific Session , Anahaim

Ãø¡¡¡¡½ñ

  1. ¾¾¸¶¹°ÌÀ¡¢´äºäÔèÆó(2001)
    ¥¢¥ó¥¸¥ª¥Æ¥ó¥·¥ó­¶¼õÍÆÂÎÙɹ³Ìô¤Î¿´Êݸî¸ú²Ì¡© (EBM½Û´Ä´ï¼À´µ¤Î¼£ÎÅ). Ãæ³°°å³Ø¼Ò 235-242
  2. ¾¾¸¶¹°ÌÀ, ´äºäÔèÆó (2001)
    Kew word ¿´Â¡ÉÂ:¥¢¥ó¥¸¥ª¥Æ¥ó¥·¥ó­¶¤È¤½¤Î ¼õÍÆÂÎ. Àèü°å³Ø¼Ò 38-41
  3. ÄÔ¡¡µ×»Ò (2001)
    ¡¡Æ°Ø©¤Ëȼ¤¦¿´ÅÅ¿Þ. Clinical Nursing Guide 23 ¿´ÅÅ¿Þ ¡Ê´äºäÔèÆóÊÔ¡Ë¡¡174¡Ý204ÊÇ. ¥á¥Ç¥£¥«½ÐÈÇ¡¢Âçºå
  4. ¿ÝëÊÝÉס¢ÌÌÚ¹¨ (1998)
    µÞÀ­º¸¿´ÉÔÁ´. ¿´Â¡É¥ץ饯¥Æ¥¤¥¹19¡Ö¥¨¥Þ ¡¼¥¸¥§¥ó¥·¡¼¤ò¾è¤êÀÚ¤ë¡×¡ÊÊÌÉÜ¿µÂÀϺÊÔ¡Ë170-176ÊÇ.ʸ¸÷Ʋ¡¢Åìµþ

Ê¿À®13ǯ¶ÈÀÓÌÜÏ¿°ìÍ÷¤ËÌá¤ë